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High quality research that changes the world is what we strive 
for at the University of  Otago Division of  Health Sciences. 
It’s also what governments around the world are asking for. 
They want greater accountability from researchers who must 
articulate how research investment benefits communities and 
populations. Those benefits include health, societal, cultural, 
economic or environmental factors at the individual, whānau 
and community level. 
This booklet describes eight research impact case studies. They 
come from across the seven Schools in the Division of  Health 
Sciences and highlight different stages of  their impact journey. 
Each has been selected for making a meaningful contribution 
in a different field of  research. 
These researchers are improving people’s health, changing 
local and central government policies, contributing to 
best practice guidelines, creating spin-off companies to 
commercialise research and building capability by training the 
next generation of  scientists. 
By forming meaningful relationships with stakeholders, 
creating strong networks with other researchers and being 
advocates for policy change they are achieving success.
We hope you enjoy discovering how their impact was achieved.
Professor Paul Brunton 
PRO-VICE CHANCELLOR, DIVISION OF HEALTH SCIENCES
introduction
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Scholarly output – all publications





Scholarly output – articles only
Total
215





publications in top 10% journal percentiles
citation count1
Field-weighted citation impact
1.99 33The Field-Weighted Citation Impact is nearly two times the world average. of our researchers have an H index of 40 or more, characterising them as ‘outstanding’ scientists.2
School of Physiotherapy
1.   Scopus. Benchmarking the publication year and scholarly output (all). Division of Health Sciences 2018. Year range: 2014 to 2018. Data source: Scopus, to 19 Jul 2019. 
2.   Hirsch JE. An index to quantify an individual’s scientific research output. Proc Natl Acad Sci U S A. 2005;102(46):16569-72.
The Division in numbers: 2014-19




Faculty of Dentistry (DENT)
School of Pharmacy
School of Biomedical Sciences (BMS) Dunedin School of Medicine (DSM)
University of Otago, Wellington (UOW) University of Otago, Christchurch (UOC)
7
Health Research Council – Sir Charles Hercus Research Fellowships
• 2019 Khoon Lim  Orthopaedics & Musculoskeletal Medicine UOC 
• 2019 Rosie Brown  Anatomy BMS
• 2019 Katie Douglas  Psychological Medicine UOC
• 2018 Htin Lin Aung  Microbiology BMS
• 2018 Hamish Jamieson  Medicine UOC
• 2018 Sharon Leitch  General Practice and Rural Health DSM
• 2018 Michael Pankhurst  Anatomy, BMS
• 2018 Daniel Ribeiro  Physiotherapy
• 2017 Tracy Melzer  Medicine UOC
• 2016 Tania Slatter  Pathology DSM
• 2015 Karl Iremonger  Physiology BMS
Health Research Council – Liley Medal
• 2017 Jonathan Broadbent  Oral Sciences DENT
Royal Society of New Zealand - James Cook Fellowship
• 2019 Hallie Buckley  Anatomy BMS
• 2018 Tony Merriman  Biochemistry BMS
• 2015 Antony Braithwaite  Pathology DSM
Royal Society of New Zealand - Rutherford Discovery Fellowship
• 2019 Olivia Faull  Pharmacy
• 2018 Sarah Diermeier  Biochemistry BMS
• 2017 Aniruddha Chatterjee  Pathology DSM
• 2015 Logan Walker  Pathology UOC
• 2014 Louise Bicknell  Pathology BMS
Royal Society of New Zealand –Hercus Medal
• 2018 Brett Delahunt  Pathology and Molecular Medicine UOW
• 2014 Parry Guilford  Biochemistry BMS
Royal Society of New Zealand – Dame Joan Metge Medal
• 2018 Suzanne Pitama  Māori/Indigenous Health Institute (MIHI) UOC
Royal Society of New Zealand Mason Durie Medal
• 2018 Lisa Matisoo Smith  Anatomy BMS 
Royal Society of New Zealand Callaghan Medal
• 2018 Helen Taylor  Anatomy BMS
• 2014 Peter Dearden  Biochemistry BMS
NZ Association of Scientists Marsden Medal
• 2018 Warren Tate  Biochemistry BMS 
Prime Minister’s Science Prizes
Prime Minister’s Science Prize 2014
 He Kainga Oranga/Housing and Health Research Programme  Public Health UOW
Prime Minister’s MacDiarmid Emerging Scientists Prize 2014
 Karl Iremonger  Physiology BMS
National Teaching Awards
Prime Minister’s Supreme Award, annual Tertiary Teaching Excellence Award 2018
 Faumuina Associate Professor Fa’afetai Sopoaga  Va’a o Tautai 
Prime Minister’s Annual Tertiary Teaching Excellence Award 2015
 Suzanne Pitama  MIHI UOC 
LIMELight Leadership Award from Leaders in Indigenous Medical Education




FELLOWS OF THE ROYAL SOCIETY 
OF NEW ZEALAND
32 of the Division’s staff  
have been elected as  
Fellows of the Royal Society  
of New Zealand
The Division in numbers: 2014-19
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National Science Challenges – 
a national initiative. 
We lead two of these
Ageing Well   
ageingwellchallenge.co.nz
Healthier Lives  
healthierlives.co.nz 
and have involvement in many others
Centres of Research Excellence
(CoREs) – a national initiative. 
We co-lead Brain Research NZ with the
University of Auckland
brnz.ac.nz 
and have involvement in many others
Genomics Aotearoa
We host this national science platform 
supporting advanced genomics research 
genomics-aotearoa.org.nz
number of students
Areas of research strength in the Division
National and international collaborations




Health Sciences EFTS 2015 2016 2017 2018 2019
PhD/DClinDent 430 431 474 480 503
Masters (thesis only) 135 134 127 133 120
Other Postgraduate 683 715 754 755 786
Total 1248 1280 1355 1368 1409
Ministry of Business,
Innovation and Employment











Royal Society of New Zealand
Addiction
Ageing





Cancer Research at Otago 
Cardiovascular Disease at Otago 



















Pacific Health Research at Otago
Public Health Research at Otago 
Suicide
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The Division in numbers: 2014-19
international collaborations
research article collaborations
the top 10 collaborating institutions
The top collaborating institutions are:
The University of Auckland   •   The University of Sydney
The University of Queensland   •   Christchurch Hospital New Zealand
The University of Melbourne   •   Canterbury District Health Board
University of New South Wales   •   Harvard University
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The Division in numbers: 2014-19
participants interviewed for thE case study
Principal investigator
Dr Dorothy Begg  Department of  Preventive and Social Medicine (retired).
Researcher 
Dr Rebecca Brookland  Department of  Preventive and Social Medicine.
Stakeholders 
Andrew Joel  former Senior Education Advisor at the New Zealand Transport Agency (NZTA),  
currently contractor and Drive Mobile Apps product owner at the NZTA. 
Jennie Gianotti  former Network Behaviour Manager at the NZTA, 
currently Manager of  Education Development at Worksafe.
Dr Simon Gianotti  former Road and Sport Team Leader at the Accident Compensation Corporation (ACC), 




Dunedin school of medicine
the new zealand drivers study
driving policy change
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(L-R) Dr Rebecca Brookland, Dr Dorothy Begg
Summary of the impact
The work of  the New Zealand Drivers Study (NZDS) has had a New Zealand and international 
impact. It successfully influenced policy and legislative changes along with road safety programme 
and campaign development. The main policy success was informing the decision to raise the 
minimum driving age from 15 to 16 in 2011. The forward-thinking research team achieved impact 
by creating relevant research questions and working closely with stakeholders and the community 
through meaningful engagement activities.
Underpinning research
At the time of  the NZDS’ establishment in 2001, motor vehicle traffic crashes were the leading 
cause of  death and injury among young adults aged 15-25 in New Zealand1. The NZDS research 
was created to provide an evidence base to facilitate policy and programmatic change aimed at 
reducing the number of  deaths and injuries. The research design specifically looked at aspects 
of  the graduated driver licensing system (GDLS) – that is progression from learner licence, to 
restricted licence, to full licence – with the aim of  determining risk factors and protective factors for 
crashes, injury and infringements for the participants.
The study was a prospective cohort study with the initial pilot running from 2001-04, and the main 
study from 2005-13. Participants were recruited to the study through Automobile Association (AA) 
and Vehicle Testing New Zealand (VTNZ) centres when they applied for their learner car licence, 
and were followed as they went through the stages of  the GDLS. Māori providers who ran driver 
licensing courses in their communities were also consulted, and recruited new drivers to the study. 
In all, 3992 new drivers were recruited to the main study and completed a baseline questionnaire 
at the time of  their learner licence test. Further interviews took place after passing the remaining 
two stages of  GDLS. Twelve hundred parents of  the youngest drivers were also interviewed at the 
restricted licence stage. Ongoing follow-up continued through official records (crashes, injuries, 
infringements).
Key findings of the NZDS:
• Most parents were in favour of  the GDLS, but many had poor knowledge about the restricted 
licence stage conditions. 
• Parents can have a considerable positive influence on their adolescents’ driving through 
ensuring compliance with the GDLS components, limiting vehicle ownership, and modelling 
safe driving behaviours2.
• One dispelled myth was that young people from rural areas had more driving experience 
prior to obtaining their learner licence, and were therefore safer drivers. The NZDS found 
that pre-licence driving had no protective effect on crash involvement at the learner or 
restricted licence stage, and that on-road pre-licence driving was actually associated with 
increased crash risk3. 
• A study looking at attitudes of  young drivers and parents to raising the licence age found that 
there was little opposition from young people to raising the driving age, and that doing so 
would have little impact on essential travel among adolescents in New Zealand4. 
• Driving before obtaining a licence was found to be common practice in both rural and urban 
Māori drivers, highlighting the need for Māori community road safety providers to address 
this issue5. 
• Drivers who were ‘non-progressors’ (did not move from a learner to restricted licence) were 
shown to have a reduced risk of  being a traffic offender in the first 2.5 years of  licensure6.
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Funding
The NZDS received approximately $3.9 million of  funding from the following funders:
• Health Research Council 
• Accident Compensation Commision 
• New Zealand Road Safety Trust (now Community Road Safety Fund) 
• National Safety Council
• Royal Society of  New Zealand
Research snapshot
• The NZDS has produced 17 research publications (cited 143 times in publications from 20 
different countries), two industry reports, and one PhD and one Masters thesis.
• Dr Begg and Emeritus Professor Langley were called on for their expertise to give a 
presentation on raising the minimum driver licence age to the Transport Industrial Relations 
Select Committee on Land Transport, Road Safety and Other Matters on 26 October 2010.
• Findings were disseminated beyond academic publication via workshops, mini-symposia and 
face-to-face meetings with interested stakeholders such as the NZTA, Ministry of  Transport 
(MOT), the Dunedin City Council, community groups and iwi.
• Results were disseminated to overseas organisations considering a change to a GDLS system. 
For example, Dr Begg was invited to provide policy advice to Sweden, VicRoads Victoria 
Australia, and present to the US National Safety Council. A paper from the latter was 
published in the Journal of  Safety Research7. 
• Dr Brookland was invited by the Royal Society (London) and the Science Advisory Council  
to the Prime Minister of  India to present at the Commonwealth Science Conference in India 
in 2014. 
Details of the impact
National
POLICY AND LEGISLATION
Findings from the NZDS informed the following legislative changes  
wand policy documents:
• The driving age was revised on 1 August 2011 from 15 to 168. 
• The Treasury document Regulatory Impact Statement: Safer Journeys  
- New Zealand’s Road Safety Strategy 2010 to 2020, which discusses  
impacts of  the minimum driving age being raised9 p12.
• The Land Transport (Driver Licensing) Amendment Rule 2014, clause 60(1)
(ca) which states that drivers can only remain on their learner or restricted car 
or motorcycle licence for five years to prevent ‘licence pooling’ (staying on the 
same class of  licence and not progressing)10. 
• In May 2011 one study was cited by Member of  Parliament Rahui Katene 
(Māori Party – Te Tai Tonga) in their parliamentary speech on the Land 
Transport (Road Safety and Other Matters) Amendment Bill11.











• Associate Minister of  Transport Hon Simon Bridges’ proposal to address driver licence 
pooling presented to the Cabinet Economic Growth and Infrastructure Committee in 2012.
• The Ministry of  Transport Regulatory Impact Statement Proposal to address driver licence 
pooling in 201212.
PROGRAMMES AND CAMPAIGNS
Multiple national road safety programmes and campaigns were undertaken by NZTA, ACC and 
Auckland Transport as a result of  the NZDS:
• The NZTA young driver programme DRIVE, a driving skills app and website13. 
• The NZTA and ACC commissioned a retrospective study from the NZDS to validate a 
theoretical model of  crash risk versus a behaviour profile in order to inform the  
DRIVE programme14.
• Findings from the study of  parental attitudes in the NZDS contributed to the development 
of  four NZTA campaigns including the Street Talk defensive driving course15  and the Safe Teen 
Driver campaign to encourage parents to stay involved in their teen’s driving. 
• Behind the Wheel Mangere (funded by the NZTA, ACC and Auckland Transport) was a local 
driving education and social marketing programme working to reduce high crash rates among 
young drivers and reduce rates of  unlicensed driving16.
International
POLICY AND LEGISLATION
NZDS studies were referenced in: 
Australia
• A submission to the Law Reform, Road and Community Safety Committee in Melbourne, Victoria 
in 2016 as part of  a case study profile of  GDLS in New Zealand17.
• The document How effective is the ACT road ready pre-licensing driver education program at changing novice 
driver risk-related attitudes and reducing the offence and crash involvement of  novice drivers in the ACT?’18.
European Union
• The European Union policy document Study on driver training, testing and medical fitness (2017)19.
• The European Commission Horizon 2020 project Safety Causation, Benefits and Efficiency 
(SafetyCube), with the objective of  developing an innovative road safety Decision Support 
System20.
United Kingdom
• The policy document Public Health Wales supports the introduction of  graduated driving licensing 
(GDL) for new drivers in Great Britain(21. In February 2018 Prime Minister Theresa May tasked 
an investigation into the possibility of  a GDLS in the UK, with a pilot scheme launched in 
Northern Ireland during 2019/202021.
• New Zealand was referenced as a case study in moving to a GDLS in the UK in the policy 
document Getting young drivers back on the road in safety by the Parliamentary Advisory Council for 
Transport Safety, UK22. 
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Pathway to impact
Characteristics of the research
• The high quality of  the NZDS research has been a key feature of  the impact achieved. 
– The large data set enabled statistically-significant conclusions to be drawn when looking 
at smaller cohorts within the data. Cross-matching of  multiple data sources provided a 
rich source of  information.
– Research questions were constructed carefully, including the addressing of  issues specific 
to New Zealand legislation, myths in New Zealand around young drivers, questions that 
were being raised in the media, as well as looking at unmet need. Addressing research 
questions relevant to stakeholders and the community was considered more meaningful 
than solely addressing what the literature highlighted as a need. This meant that the 
research outcomes could be readily applied and used in practice.
“‘ Impact means research can be applied straight away –  
we’re constantly looking for applied research that we  
can literally buy off-the-shelf.” 
Andrew Joel   FORMER SENIOR EDUCATION ADVISOR,  
NEW ZEALAND TRANSPORT AGENCY
Engagement
• Proactive engagement with the community was vital. While this required significant 
investment in time and money, it was considered worthwhile in order to translate the research 
into impact. Face-to-face meetings with community groups and iwi enabled meaningful 
consultation on project development and feedback on the research plans. This took place 
prior to commencement of  the main study and continued throughout the project. A key 
objective of  the pilot study was relationship building. Meetings took place in the participants’ 
communities – Hawke’s Bay, Gisborne, Ruatoria, Auckland, Christchurch, Dunedin and 
Invercargill. Through this engagement, researchers were able to recruit a good representation 
of  rural, urban, Māori and non-Māori participants. 
• Keeping in close contact with stakeholders was key to achieving impact. This was particularly 
important in organisations where there was relatively rapid staff turnover (for example, 
government agencies). 
“ Get out there, make sure people know who you are and what 
you’re doing. Especially the people who are likely to be 
influenced or affected by your research.” 
 Dr Dorothy Begg   PRINCIPAL INVESTIGATOR, NEW ZEALAND DRIVER’S STUDY
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Awareness of the policy environment
• An awareness of  the policy environment and potential implications of  policy change was 
crucial, including:
– Taking advantage of  policy windows and opportunities; for example understanding 
timings enabled a submission to be made prior to the driving age legislation being 
debated in parliament.
– Anticipating the effect of  policy changes by conducting research on this; for example, the 
impacts of  potentially raising the driving age were anticipated by asking young people 
what the effects on them would be. 
A targeted approach
Stakeholders interviewed expressed their appreciation for proactive engagement 
and a targeted approach to research and dissemination from the NZDS 
researchers. Andrew Joel from the NZTA said “They’ve been very approachable and 
eager to discuss research, and shared early findings with me. They’ve been very prepared to come 
and help speak to stakeholder gatherings or participate in workshops. It just has more impact 
when you have the actual researchers available to answer questions”. Dr Simon Gianotti of  
ACC said “It taught us that we had to keep refreshing our products. It also taught us how to 
communicate and talk to the young people, what was of  relevance to them, and how to work 
with different age groups. It told us more about who we’re trying to target, how we’re trying to 
target them, and what would be the best way to do it.”
What next?
• Rebecca’s driving research is continuing with a focus on improving health and wellbeing 
outcomes in older adults. She has a current HRC project; NZPATHS: NZ Prospective Older Adult 
Transport and Health Study (2018-2022).
• Rebecca has continued her involvement in young driver research. She is: 
– Co-investigator on the Evaluation of  the Dunedin Community Driving Programme project,  a 
programme run by NZ Police to assist youth traffic offenders to progress through GDLS.
– Associate Investigator on the Australian young driver DRIVE Re-linkage project. (DRIVE is 
Australian equivalent to NZDS)
– Associate Investigator on the Australian led The Road to Compliance: Integrating Three  
Theories project.
• For the NZDS, further follow-up of  crash, injury and infringement data is currently being 
explored.
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participants interviewed for thE case study
Principal investigator
Professor Philippa Howden-Chapman  Director, He Kainga Oranga;  
Chair of  WHO Housing and Health Guidelines Development Group;  
Director of  the New Zealand Centre for Sustainable Cities
Researchers 
Associate Professor Michael Keall  Programme Co-director, He Kainga Oranga
Associate Professor Nevil Pierse  Programme Deputy Director, He Kainga Oranga
Professor Julian Crane  Programme Co-Director, He Kainga Oranga
Professor Michael Baker  Programme Co-Director, He Kainga Oranga
Team member
Shirlee Wilton  Former Research Manager, He Kainga Oranga
Stakeholders 
Cheryl Davies  Manager, Tū Kotahi Māori Asthma Trust




He kainga oranGa, housing and health
Improving health outcomes 
through housing policy change
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university of otago, wellington
(L-R): Professor Robyn Phipps, Associate Professor Michael Keall, Professor Chris Cunningham, Associate Professor Michael Baker, 
Associate Professor Nevil Pierse, Professor Julian Crane, Dr Manfred Plagmann, Professor Philippa Howden-Chapman, Jasmine Xu
Summary of the impact
The He Kainga Oranga, Housing and Health research group, led by Professor Philippa Howden-
Chapman at the University of  Otago, Wellington, has had outstanding impact over the past two 
decades. Research has been directed at policy change and improving housing quality, with the 
ultimate goal of  improving health outcomes for New Zealanders. Factors enabling success include 
an interdisciplinary team researching a wide range of  housing and health topics, and developing 
close relationships with the community, including Māori. Strong leadership and a supportive and 
collaborative culture have also been key.
Underpinning research
The He Kainga Oranga research group has a large body of  research addressing housing as a 
determinant of  health — based on the premise that housing quality affects the health of  the 
inhabitants. The research includes both social and environmental elements such as overcrowding 
and indoor air quality. Interventions for improvement include insulation, heating and injury 
prevention. Ethnic inequalities are also addressed through research undertaken with Māori 
communities. More recent studies are investigating rental properties and legislation,  
and homelessness.
The first significant piece of  work produced by He Kainga Oranga was the Housing, Insulation and 
Health Study led by Philippa and Professor Julian Crane, who co-founded He Kainga Oranga in 
19981. 1350 council houses around New Zealand were retrofitted with insulation, in partnership 
with the Energy Efficiency and Conservation Authority/Te Tari Tiaki Pūngao (EECA). 
Households with at least one occupant with a chronic respiratory condition were chosen for the 
intervention. Results showed that occupants’ health and wellbeing improved, as did household 
energy efficiency. The economic benefits of  retrofitting insulation in New Zealand was found to 
have a benefit-cost ratio of  4:1.
Another important study, The Housing, Heating and Health Study was a randomised community trial 
led by Philippa and Associate Professor Nevil Pierse (2008)2. It investigated the effects of  installing 
improved heating in 409 insulated households where there was a child with asthma. The study 
showed that indoor temperatures increased significantly and the health status of  the children 
improved, with lower levels of  asthma symptoms and sleep disturbances, as well as fewer days 
absence from school. In the Evaluation of  Warm Up New Zealand: Heat Smart report, a benefit per year 
of  $563.18 for retrofitted insulation and $4.64 for improved heating was calculated per household, 
due to reduction in total hospitalisations, pharmaceutical use, and mortality3. 
Nevil then worked with Associate Professor Michael Keall on the Housing Injury Prevention Intervention 
(HIPI) study, finding that simple home repairs and modifications such as putting in grab rails in 
bathrooms reduced the number of  falls in homes by 27%4. A preliminary analysis of  the pilot 
showed the benefit-cost ratio of  this home remediation was 9:1.
Further key studies led by Professor Michael Baker focused on environmental health, infectious 
disease and housing. His research showed household crowding is the single biggest risk factor for 
meningococcal group-B infection5 and rheumatic fever6. 
He Kainga Oranga have collaborated with BRANZ since their inception, and their combined 
research has linked aspects of  building physics (such as ventilation) to health effects on occupants. 
BRANZ has produced a report on the role of  ventilation in managing moisture inside New 
Zealand homes, highlighting the importance of  this in creating a healthy indoor environment7. 
Philippa and Nevil are on the advisory board of  the Warmer, Drier and Healthier Homes 
Research Programmes at BRANZ.
“ I want people to have a better life because of  the research  
I’ve done. I want people to be happier and healthier.” 
 Associate Professor Nevil Pierse   DEPUTY DIRECTOR, HE KAINGA ORANGA
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Funding
He Kainga Oranga has received over $20 million in funding since 1998. Major funders include: 
• The Health Research Council (HRC), including $10 million in programme grants
• The Ministries of  Business Innovation and Employment; Health; and the Environment
• Royal Society Te Aparangi
• Cure Kids  
• Asthma Foundation
• Accident Compensation Corporation
• Housing New Zealand Corporation




The key, world-leading, papers produced by He Kainga Oranga are:
1. The housing, insulation and health study: Effect of  insulating existing houses on health inequality: 
cluster randomised study in the community. This was the cover story of  the BMJ in 20071.
2. The housing, heating and health study: Effects of  improved home heating on asthma in community 
dwelling children: randomised controlled trial. Published in the BMJ in 20082.
3. The injury prevention study: Home modifications to reduce injuries from falls in the home injury 
prevention intervention (HIPI) study: a cluster-randomised controlled trial. Published in The Lancet in 
20154.
The three main studies:
• Have been cited in 457 academic publications indexed by Scopus.
• Have rankings in the 98th, 84th and 97th percentiles of  citations, respectively, in the field of  
medicine (Scopus).
• Have had 16 media mentions, including ABC News Australia.
• Have been cited 3 times in reports on the New Zealand Parliament website and 9 times in 
submissions to Parliament.
• Are all in the top 5% attention scores by Altmetrics.com.
An additional 63 academic publications from He Kainga Oranga have been cited 790 times by 
researchers in 79 countries (Scopus). 
Key reports:
1. Warming up New Zealand: Impacts of  the New Zealand Insulation Fund on Metered Household Energy Use 
(2011)8.
2. Cost benefit analysis of  the Warm Up New Zealand Heat Smart Programme (October 2011, revised July 
2012)9.
3. The impact of  retrofitted insulation and new heaters on health services utilisation and costs, pharmaceutical 
costs and mortality (2011)3.
4. Impacts of  the NZ Insulation Fund on Industry and Employment (2011)10.
These reports have been cited 21 times in national and 18 times in international reports, and three 
times in submissions to Parliament.





World Health Organisation Housing and Health  
Southern Hemisphere Guidelines Launch 
The Southern Hemisphere launch of  the World Health Organisation Housing 
and Health Guidelines was held at the University of  Otago, Wellington in 
February 2019. The guidelines group was chaired by Professor Philippa 
Howden-Chapman. This event was both a celebration of  the launch of  the 
guidelines and an important step in their dissemination, as it brought together 
stakeholders from industry, research and politics, including Hon James Shaw, 
MP (Co-leader Green Party, Minister for Climate Change, Associate Minister of  
Statistics, Associate Minister of  Finance), and Dr Ashley Bloomfield, Director 
General of  Health. These guidelines are the first sector guidelines produced by 
the World Health Organisation11. 
“ The World Health Organisation’s International Housing and 
Health Guidelines provide important and useful advice for us 
to bear in mind when formulating better policy for our people. 
They not only show us what needs to happen to provide better 
futures for our citizens and their families, but they help us to 
decide how it should happen, and perhaps most importantly, 
why it needs to happen.” 
 Hon James Shaw, MP.  
 CO-LEADER GREEN PARTY, MINISTER OF CLIMATE CHANGE,  
 ASSOCIATE MINISTER OF STATISTICS,  ASSOCIATE MINISTER OF FINANCE20
Details of the impact
National impact
POLICY AND PROGRAMME DEVELOPMENT
• The Rental Warrant of  Fitness programme was created through collaboration between the 
University of  Otago and the New Zealand Green Build Council (NZGBC), in consultation 
with other organisations. It provides a manual and a room-by-room checklist for rental 
properties to ensure they are of  appropriate condition13, 14.
• Well Homes is a free programme run in conjunction with the Sustainability Trust, Tu Kotahi 
Māori Asthma Trust, and Regional Public Health, aiming to reduce crowding and to assist 
whānau in making their homes safe, healthy and dry15.
• The Cross-Party Inquiry on Homelessness (2016) was informed by the work of  He Kainga 
Oranga. The report’s first recommendation was to roll out Housing First as the primary 
response to severe homelessness16. The Housing First programme started with $2.5 million in 
pilot funding with a further $63.4 million invested in 201817. Through Housing First, 2,700 
people now have permanent, warm, dry housing18.
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• BRANZ and He Kainga Oranga provided extensive research input underpinning the 
formulation of  The Healthy Homes Guarantee Act 2017, which came into force on 1 July 201919. 
The Act legislates that landlords must comply with a healthy homes standard, including 
standards on indoor temperature, heating, insulation and drainage. New standards were 
announced in February 201920. 
• The Warm Up New Zealand programme run by the Energy Efficiency and  
Conservation Authority/Te Tari Tiaki Pūngao (EECA) has spent close 
to one billion dollars insulating over 300,000 houses through work  
with He Kainga Oranga15. The Government has pledged another  
$142.5 million to cover the costs of  ceiling and underfloor 
insulation for thousands of  low-income homeowners. That 
investment was boosted at the start of  2019 by nearly $5 million  
from community organisations, councils, charitable trusts, and  
DHBs20. This additional funding has resulted in 3,200 homes  
being insulated as of  February 201920. 
“ I think the great thing about this programme was it pushed 
governments to do something that they might not have done,  
in a big way”. 
 Professor Julian Crane   CO-DIRECTOR, HE KAINGA ORANGA
HEALTH AND WELLBEING
• Countless individuals, including over 10,000 research participants, as well as those who have 
benefitted from consequential government subsidies and minimum housing standards, have 
benefitted from warmer, healthier homes. Improved housing standards have also helped to 
address health inequalities by addressing social and environmental inequalities. 
ENVIRONMENTAL
• Better housing standards reduce heating emissions, leading to impact on the environment 
through reduced heat loss and energy usage, thus reducing contributions to climate change.  
ECONOMIC
• The cost-benefit analysis of  the Warm Up New Zealand: Heat Smart programme had showed an 
estimated net benefit of  $950 million9 p iv. Now that the programme has been rolled out and 
extended, it is estimated to have delivered $2 billion of  benefit to New Zealand. 
• Improved housing standards lead to less time off work or school due to fewer sick days, and a 
reduced burden on the health system.
• Improvements in housing mean that energy insecurity is reduced, as well as the cost of  
heating for home occupants.
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• Highly accomplished leadership has been the driving force behind the success of  He Kainga 
Oranga. This has resulted in a cohesive, high-achieving team and a culture of  mutual support.
• Team meetings are a key feature of  how the team work - team members share stories of  what 
is, and what isn’t working in their research and what help they need. 
Research Framework and Quality 
• He Kainga Oranga has a firm conviction to undertake research with a strong public health 
focus. They have recognised that a systematic approach is key, including addressing economic, 
social, environmental, and cultural issues. 
• Working as an interdisciplinary team (encompassing biostatistics, public health, medicine and 
psychology) has enabled them to provide high-quality evidence to a wide range of  research 
questions.
• The ability to think ahead and think strategically, including looking at overseas research and 
policy, has helped to produce high-quality research. 
Engagement with the community
• He Kainga Oranga has shown a strong commitment to ongoing community engagement.
• Engagement involved research participants, the wider community, and Māori and Pasifika 
stakeholders. Although engagement requires investment of  money and time, it means there 
can be a long-lasting, beneficial relationship for both parties.   
• Community goodwill has been vitally important. Community partnerships  
have led to participant retention rates in the research studies of  over 80%.
“ We adopt a philosophy of  what Fred Hollows said:  
‘there should be no survey without service’ ”. 
 Professor Philippa Howden-Chapman    
 DIRECTOR, HE KAINGA ORANGA
• He Kainga Oranga has had meaningful, long-term relationships with Māori  
researchers and Māori community organisations, and the Tū Kotahi Māori Asthma  
Trust in particular. Feeding back on findings enables participants to feel valued and supported. 
“ My big piece of  advice is to develop, or establish, a meaningful 
relationship with Māori. If  you have a Māori provider that 
you’ve done work with previously, don’t just finish with that 
study and then only go back to them maybe five years later.  
It goes a long way when you nurture that relationship and  
you keep that relationship going.” 
 Cheryl Davies   MANAGER TŪ KOTAHI MĀORI ASTHMA TRUST
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Translation into policy
• A strategy used to increase the translation of  He Kainga Oranga’s research into policy is 
to present findings in the form of  economic analysis reports, which provide the real-world 
economic benefit of  implementing recommended changes3, 9. 
• Research can provide compelling evidence on issues which urgently need addressing. For 
example, the finding that 28,000 children were hospitalised every year with housing-preventable 
diseases, and 853 died within a 15-year period, is difficult for policy makers to ignore.
• Partnership with, and responsiveness to, policy makers/analysts is key to success. If  a Minister 
wants information, then the request is prioritised.
• The team constantly engage with policy makers to ensure that their research is kept on the 
agenda. This means, at minimum, three-monthly meetings with research users. 
“ The real kicker to getting that impact over the line is somebody 
who has the ability to pick it up and make a difference, and is 
working in the right place to make that difference. We make a 
lot of  noise to keep it on the agenda.” 
 Associate Professor Nevil Pierse   DEPUTY DIRECTOR, HE KAINGA ORANGA
Stakeholder engagement
• Early and proactive stakeholder engagement has been vital, and considered the groups 
that may be interested in the work, and those who might be affected by potential change. 
Examples include community NGOs involved in housing, health, poverty or Māori 
development; Ministries; other government bodies (EECA, BRANZ, Housing New Zealand 
and Māori Boards); and visiting academics. 
• Early stakeholder engagement has also been important for strengthening grant applications as 
it shows that researchers have thought about who to work with and what impacts may ensue.
• Relationships with stakeholders are built on mutual respect, co-ownership of  the research, and 
an understanding that each party brings different skills to the table.
• Stakeholders are invited to participate in weekly group meetings. 
Capacity building
• He Kainga Oranga is devoted to supporting students and nurturing new researchers. For 
example, Philippa has supervised an estimated 20 PhD, 14 Masters, 15 summer and 15 
visiting students, many of  whom have gone on to become team members. 
• The team is involved in Otago University’s Public Health Summer School, led by Michael 
Baker. The school has evolved over 12 years to become one of  the largest public health 
summer schools in the world. 40% of  attendees are government staff.
Dissemination of results
• Prior to the research there was little knowledge of  housing having an impact on health, 
and the media has been vitally important in getting this message to the public. The team 
frequently issue press releases. Public interest in housing means that the researchers are often 
called on for comment. 
• Getting the research into the WHO guidelines was key to initiating change in policy making.





• Nevil currently leads the Housing First research, with the aim of  reducing the number of  
people sleeping rough in New Zealand streets by 90%.
• Michael Keall is leading a further injury prevention study, called Safety on Steps. This 
randomised controlled trial builds on the findings of  the injury prevention study.
• He Kainga Oranga and Tu Kotahi Māori Asthma have a project called He Tipu Manahau, 
which is based around the development of  affordable, good-quality housing in Wainuiomata 
using the concept of  Ko Toku Kainga.  
• Warm Hearts is a follow up study to Warm Homes for Elderly New Zealanders and is being undertaken 
with the support of  Tū Kotahi Māori Asthma Trust. This study continues to monitor a sub-
group of  initial study participants, and is particularly concerned with cardiac outcomes.
• An eviction study led by Philippa is looking at understanding the experience of  those who 
have been evicted from their homes, as well as views from other stakeholders, including the 
courts, social workers and community workers.
FOR MORE INFORMATION ON HE KAINGA ORANGA, SEE THEIR WEBSITE AT  
www.healthyhousing.org.nz
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World-leading research in phage 
and CRISPR-Cas systems 
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school of biomedical sciences
Professor Peter Fineran
Summary of the impact
Professor Peter Fineran leads a research group in the Department of  Microbiology and 
Immunology at the University of  Otago. The impact of  his internationally-renowned research 
has been to advance knowledge of  how CRISPR-Cas systems are regulated, and how they work 
as ‘molecular scissors’ to cut genes. Peter has also had impacts in increasing public knowledge of  
science and building capability of  students and scientists in the CRISPR-Cas arena. Applications 
to industry, as evidenced by his work on bacteriophage strategies to manage the Psa infection in 
kiwifruit, have also been impacted by Peter’s research. Peter’s success has come through high-
quality research disseminated widely to the scientific community and public, as well as close 
collaboration with industry.
Underpinning research
Professor Peter Fineran‘s main research interests are the bacteriophage-resistance mechanisms 
of  bacteria. Bacteriophages (also known as phages) are viruses which infect bacteria1. Bacteria 
have their own ‘immune systems’ called CRISPR-Cas, just as humans have theirs. The bacterial 
CRISPR-Cas systems destroy invading phages and can also prevent bacteria from acquiring 
antibiotic-resistance genes.
Peter’s main research goal is to understand the interactions between phages and their bacterial hosts. 
This involves understanding how these CRISPR-Cas immune systems work, including when bacteria 
use this immune response, how bacteria are able to communicate with each other, and how they gain 
‘memory’ of  phage attack. Peter is also interested in the potential real-world applications of  phages, 
such as their use as antimicrobial agents. Peter’s world-leading work has shown how CRISPR-Cas 
systems are regulated, and how they work as ‘molecular scissors’ to cut genes.  
CRISPR-Cas systems are used for gene editing, diagnostics, regulating gene expression and related 
technologies1, with the potential for a wide variety of  applications in other research, biomedical 
therapies, and genomic editing of  organisms. Applications of  genome editing are depicted below2 p4 
(Figure 1):
FIGURE 1:  APPLICATION OF GENOME EDITING
(Modified from Hsu et al. 2014)
The extension of  CRISPR tools into human genome editing has fundamental ethical issues, which 
are currently being debated amongst scientists and the public3. Peter has been a public figure in 
these discussions, such as by participating in public talks4.
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Currently, Peter is investigating the potential use of  phages as a biocontrol agent against the 
Pseudomonas syringae pv. actinidiae (Psa) pathogen. Psa is a bacterium which causes kiwifruit canker. It was 
first discovered in New Zealand in November 2010 and in 2011 Peter started working with Zespri 
International Limited, the world’s largest marketer of  kiwifruit to develop phage-control strategies.
Funding
Peter’s work has had over $6 million to date from a number of  funders, including: 
• Rutherford Discovery Fellowship and Marsden Fund, Royal Society Te Apārangi
• Zespri International Ltd.
• Tertiary Education Commission, NZ, via the Bio-Protection Centre of  Research Excellence
• European Research Commission, European Union
• Ministry for Business Innovation and Employment
Collaborations  
Peter has extensive collaborations – 12 national collaborators from eight organisations, and 15 
international collaborators from nine institutions in six different countries.
Research snapshot
• Peter has produced 46 publications on phage and/or CRISPR-Cas systems, cited 2070 times 
in Scopus and averaging 46 citations per publication. 
• Peter has been involved in producing documents designed to provide information to the 
public, such as the Royal Society fact sheet on gene editing2.
• Peter has contributed to submissions to Government with the aim of  influencing science 
policy, e.g. a response to the National Statement of  Science Investment draft in 20146, and the 
Ministry of  Business, Innovation and Employment’s The Impact of  Science in 20177.
• Peter has been an invited presenter at ~25 conferences (mostly international).
• Peter participates in events to engage the public in the science around CRISPR  
technology, including a panel discussion at the LATE at the Museum event at  
Auckland Museum, also broadcast on Radio New Zealand4,5. 
• Peter is regularly called on by the media to comment on CRISPR technologies.  
A recent example was the New Zealand Geographic in 20178. 
• Peter has talked to Members of  Parliament as part of  the Science Speaker Series  
discussing CRISPR technologies. 
• 12 of  Peter’s articles on CRISPR-Cas and phage have been cited in 58  
granted patents.
Recognition
Peter has received a number of  international and national awards, including:
• 2019 Alexander von Humboldt Experienced Researcher Fellowship, Germany
• 2019 Fleming Prize, Microbiology Society, UK  
• 2017 Genetics Society of  AustralAsia Ross Crozier Medal 
• 2017 Andrew Shelling Trophy, NZ
• 2015 NZ Society for Biochemistry and Molecular Biology Custom Science Award
• 2015 Thermo Fisher Scientific Award, for Excellence in Molecular Biology, NZ 
• 2012 Rutherford Discovery Fellowship, Royal Society of  New Zealand 
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Details of the impact
Advancing knowledge
• Peter’s work has advanced scientific knowledge around the role of  CRISPR-Cas defence 
mechanisms of  bacterial populations, enabling further research and development to take place 
in the field. 
• Through wide dissemination of  his work, Peter is now recognised amongst scientists as an 
expert on CRISPR-Cas, increasing the reputation of  the University of  Otago.
• Peter’s public outreach has increased knowledge of  CRISPR-Cas technologies in the public 
domain. Due to the potential ethical implications of  CRISPR technologies it is important the 
public is well informed and takes part in decision-making. 
Building capability
• Over 50 students and staff have trained and worked in the Peter’s lab in the past 10 years,  
expanding their knowledge and research capability. A number have gone on to run their  
own laboratories overseas. 
• Capability development increases the potential for translation to other aspects of  basic 
science, for example findings on the phage mechanism of  Psa may be transferred to other 
bacterial pathogens of  medical importance.
• The movement of  trained staff to other institutes has enabled phage and CRISPR research to 
be undertaken in organisations where there was previously no capacity in this area.  
For example, Dr Rebekah Frampton moved from Peter’s lab to Plant & Food Research, which 
has enabled students and technicians in the organisation to build their capability  
with CRISPR technology.
Translation to applications 
• With regard to Psa, Peter’s CRISPR research is allowing the development of  phage-control 
strategies to be tailored and applied in a more specific manner. This may ultimately lead to 
better crop yields and associated economic impacts. There are also potential environmental 
impacts as it would reduce the use of  harmful agrichemicals and antibiotics, ultimately 
preventing antibiotic-resistance, one of  the biggest threats to the world’s food security9.
• CRISPR-Cas mechanisms are now used as DNA editing tools in research environments. 
These tools have accelerated research into treatments for certain human genetic disorders 
such as sickle cell anaemia The rapidly-expanding biotechnology industry built on CRISPR-
Cas genome editing now exceeds one billion US dollars, and Peter’s research has broadly 
informed this work. 
“ CRISPR tools now are being applied across all different 
research areas of  biology. So, anyone who wants to understand 
how any organism works, can now use CRISPR to mutate or 
control a particular gene. There’s huge impact from that.” 
 Professor Peter Fineran  DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY, 
 SCHOOL OF BIOMEDICAL SCIENCES





Characteristics of the research
• Peter has created his own niche in the field by undertaking novel research. This has allowed 
him to generate impact in a highly competitive area of  research.
• The research programme is highly cohesive with all projects interconnected into the theme 
of  phage-bacterial interactions. This allows the scientists to collaborate, help each other, 
troubleshoot, and share what works.
• The research is scientifically excellent, making it of  high value to other scientists and 
stakeholders. For example, 58 granted patents cite Peter’s research.
• The choice of  research that is applicable to multiple areas (e.g. biotechnology, agriculture, 
human health, society) has allowed it to have widespread actual, and potential, impact.
Engagement 
• Peter has actively sought engagement with industry. He approached the industry stakeholder 
Zespri after the 2010 Psa outbreak and they agreed to fund this work. 
• Engagement with the public has been important for increasing understanding and awareness 
of  the role of  science in society. This engagement has provided Peter with feedback on his 
research, allowing him to understand different perspectives on his research, and gauge the 
interest in his work.
• Peter has met with kiwifruit growers to gain insight into the environment in which the 
research is hoped to provide impact.
• Taking media opportunities as they arise has been important for disseminating the  
research message. 
 “ Unintended things – those won’t happen if  you don’t engage. 
If  you just sit in your lab, sit in your office, those doors won’t open.” 
 Professor Peter Fineran  DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY, 
 SCHOOL OF BIOMEDICAL SCIENCES
Teamwork and collaboration
• Relationships with organisations that are potential avenues for delivering impact, such 
as Plant & Food Research and Zespri, have been prioritised.
• Peter utilises people close to the end-user (for example, Dr Sonia Whiteman 
from Zespri), understands their strengths and involves them in discussions, 
thereby creating teams of  people involved in creating impact.
• Attending and presenting at conferences has been an excellent tool 
for keeping up to date with advances in the field and setting up new 
collaborations.
• Sharing lab meetings with researchers from other areas is a good way of  being 
exposed to different research perspectives.
• Peter works with overseas groups to undertake research for which there is currently  
no technological capability in New Zealand. For example, collaborating with Associate 
Professor Richard Scheltema and Professor Albert Heck’s world-leading proteomics 
laboratory in The Netherlands* has enabled the study of  protein complexes and Cas  
protein complexes by mass spectrometry and crosslinking. 
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 *University of Ultrecht
Dr Sonia Whiteman
Communication skills
• Strong communication skills have been important for building networks and relationships.
• Clear communication with end-users has been vital. This includes being honest about 
limitations, being open to constructive criticism and allowing end-users the opportunity to 
make informed decisions. 
• Presenting research in a way that is understandable to a non-specialist audience  
is important when engaging with stakeholders and the public. 
“ Have a good story. You’ve got to connect with the people who are 
funding you, and with who it’s going to make a difference to.” 
 Dr Rebekah Frampton   RESEARCH ASSOCIATE,  
 PLANT AND FOOD RESEARCH
What next?
• The ultimate aim of  the Psa research is to create a product to control or eliminate Psa. This 
will require a commercialisation process, and finding a pathway to market which may result in 
economic benefit for the researchers and stakeholders. 
• Research will continue into understanding how CRISPR systems work and how they can be 
exploited. This has potential impact for understanding and halting the spread of  antibiotic 
resistance. 
• Within the team, there is opportunity to develop new diagnostic tools around CRISPR-Cas, 
and move into the applied space.  
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Associate professor peter Mace
one step closer to cancer treatment 
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school of biomedical sciences
(L-R): Associate Professor Peter Mace, Sam Jamieson, Dr Anita Dunbier
Summary of the impact
Associate Professor Peter Mace is a biomedical scientist who discovered several structures of  a 
protein with an important role in inflammation, as well as potential roles in some cancers. Impacts 
of  Peter’s research to date include building capability in students and staff, creating collaborations 
and advancing knowledge. Peter has achieved this by addressing knowledge gaps, trying new ideas, 
building relationships, and disseminating his research findings widely. Potential future impacts 
include using the protein as a drug target for the treatment of  cancer. 
Underpinning research
Associate Professor Peter Mace is a structural biologist. The wider aim of  his research is to discover 
the 3D structure of  proteins and the influence of  structure on function. From his initial discovery 
in 2014, several structures of  a protein called Tribbles have been solved1,2. Tribbles is encoded by 
the TRIB1 gene, which is important in inflammation and cancer. The Tribbles protein family is 
named after a small, furry creature from Star Trek that reproduce rapidly3. Within the cell, the 
protein produced from the TRIB1 gene plays diverse roles in cell development and signalling4. 
In 2013 Peter established his laboratory with funding from a Rutherford Discovery Fellowship 
in the Department of  Biochemistry at the University of  Otago. Peter initially looking at the 
basic biology of  proteins similar to Tribbles, then investigating Tribbles sequences. There was no 
structural information about these proteins, so there was space in the field to research fundamental 
aspects of  the 3D shape of  these proteins and how they work. Peter found that Tribbles proteins 
were highly expressed in many cancers, such as breast cancer, and finding their structure and 
function could potentially lead to using them as a therapeutic target for drug development. Peter 
is leading the discovery of  the structure of  these proteins internationally, with several groups 
interested in the protein’s function. Overall, Peter’s research has resulted in a greater understanding 
of  how Tribbles proteins are interacting at a cellular level, and what the consequences are of  those 
interactions1, 2.
Peter and his collaborators* produced the first 3D images of  the Tribble-1 using the Australian 
Synchrotron, which uses powerful X-ray beams to image a protein’s structure5. Peter’s team 
discovered that Tribble-1 does not have kinase activity, but has a switch-type mechanism when it 
binds substrates as the active site opens up. The major implication of  this is that a large pocket 
then becomes available where potential small molecule drugs could bind. Research has shown 
that Tribbles-1 promotes acute myeloid leukaemia, and suggest it could also be involved in breast 
cancer, so the development of  a drug targeting Tribbles-1 could improve outcomes for cancer 
patients. Breast cancer and leukaemia have the greatest and the 10th-greatest incidence of  all cancers 
in New Zealand, with 87.3 people and 8.8 people affected per 100 000 respectively. The annual 
public cost of  breast cancer is $76.8 million (based on 2008 figures) and $68.5 million for leukaemia6, 7. 
Breast cancer researcher Dr Anita Dunbier, who is also in the Department of  Biochemistry, 
collaborates with Peter to explore the connection between breast cancer and Tribbles. Peter 
approached Anita after he found that Tribble-1 was over-expressed in breast cancer; together they 
have co-supervised a PhD student Hamish McMillan whose work is focused upon understanding 
the protein’s interactions. A key part of  the project used a novel technique called Rapid 
Immunoprecipitation of  Endogenous Proteins (RIME), enabling researchers to examine the protein 
in the cell in a natural situation to identify the other proteins with which it is interacting, revealing 
more about its function and potential role in breast cancer. 
Peter is also collaborating with Dr Karen Keeshan’s† laboratory to investigate the role of  Tribbles 
proteins in leukemia. Her lab is working with mouse and human models of  leukemia, which is one 
further step nearer to human studies. They are also developing protein reagents that specifically 
change levels of  Tribbles proteins, which may be applicable in cancer-specific models.
*  Structural work was performed with Sam Jamieson, and contributions from Yoshio Nakatani (Otago) and James Murphy (Walter and Eliza Hall Institute, Melbourne)
† University of Glasgow
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After receiving additional funding from the Health Research Council (HRC), Peter continued to 
carry out structure determination studies and develop research capability through supervision of  
an assistant research fellow and senior technician in the lab, and co-supervision of  PhD students. 
Funding
• HRC, $1.13 million over 3.5 years.
• 2012 Rutherford Discovery Fellowship from the Royal Society of  New Zealand, $920,000 
over 5 years – generation of  preliminary insight
• Lotteries Health Research – indirect funding of  equipment that was integral to the research 
• New Zealand Synchrotron Group (MBIE and Otago) 
• Contract research income from the drug company
Research snapshot
• Peter has two academic publications on Tribbles6, 7. These publications have been cited in 38 
academic articles from 13 different countries.
• Peter has been invited to present his research three times in the USA and three times in 
Europe. Conferences were organised by the Biochemical Society and European Molecular 
Biology Organization in Europe, and the American Society for Biochemistry and Molecular 
Biology in the USA (twice). Other seminars were at research institutes or companies.
• Peter spoke about his research on Channel 9 news, and articles were published on his research 
in the New Zealand Herald8, the Otago Daily Times9, and stuff.co.nz10.
• Peter has academic collaborations with James Murphy and Isabelle Lucet (Walter and Eliza 
Hall Institute, Melbourne) Anita Dunbier (University of  Otago) Natarjan Kannan (University 
of  Georgia), and Alison Axtman (University of  North Carolina).
• Peter is collaborating internationally with one drug and one biotechnology company. 
Details of the impact
Capacity building
• Peter has taught biomedicine to students who go on to work in different fields. For example, 
Peter teaches in the Bachelor of  Science programme, with students going on to a variety of  
science careers, and some into medicine.  
• Peter also plays a major role in the Department of  Biochemistry crystallography group and 
through this is assisting and training a wider group of  researchers in synchrotron science and 
structural biology.
• Hamish McMillan is a PhD student of  Māori descent co-supervised by Peter and Anita who 
won the European Society for Medical Oncology award at the NZ Society for Oncology 
Conference in 2018, for his talk The Role of  Pseudokinase TRIB1 in Breast Cancer.   
He was the Elman-Poole Scholarship and Majorie McCallum travel award in 2018 to travel to 
the UK and learn further techniques. 
• Senior technician Sam Jamieson, who is of  Māori descent, now manages the structural 
biology resources in the department (after building experience specifically in this project),  
and will continue to be an integral member of  the research workforce. 
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economic
• Through the relationship with the drug company, the lab has been able to undertake contract 
work, screening samples, thus bringing income to the department to support more research.
Advancing knowledge
• Discovery of  the Tribbles-1 structure has advanced scientific knowledge in this area. Other 
research groups have gone on to use the structural findings with Tribbles-1 to draw conclusions 
on related Tribbles proteins, which also have roles in cancer and metabolic diseases. 
• The knowledge generated has drawn attention in the wider field of  pseudokinase biology, by 
demonstrating potential for drug targeting of  this type of  protein. 
Potential impacts
• Several industry groups are now interested in partnering with Peter to  
characterise Tribbles-binding drugs. This means that they are screening  
for compounds that bind to Tribbles-1, or will develop these  
compounds themselves. 
• The ultimate impact that this research is working towards is that a drug  
will be designed and applied that targets Tribbles and reduces the burden  
of  cancer and helps people to achieve better health outcomes.
• Through collaborations with a biotechnology company, it is hoped  
Peter’s lab may be able to both advance compound development and  
aid workforce development by giving researchers at Otago experience in  
collaborative drug discovery.
“ The work we do is at one end of  the process, it might be 
several steps removed from getting to a patient, but I feel 
like if  we can see how proteins work by solving their 
3D structures, inherently other people who’re studying 
those proteins are going to find they’re useful. I feel 
like that’s having impact.”  
 Associate Professor Peter Mace    
 DEPARTMENT OF BIOCHEMISTRY, 
 SCHOOL OF BIOMEDICAL SCIENCES
Pathway to impact
Characteristics of the research
• Peter has identified that an important part of  this research has been filling a knowledge gap 
of  the structure of  the Tribbles proteins. Interest has been created around his work as it is 
novel and of  high quality. Novel research also helps to attract grant funding.
• Peter feels it is important that this research is of  benefit to other researchers. By working  
with researchers looking at the function of  Tribbles proteins, Peter’s research is able to 
inform other people’s research and thus broadens the opportunities for the knowledge to be 
translated into outcomes.
• Being prepared to try new things is important in this type of  discovery research. This includes 
trying to come up with new analytical techniques in order to push the boundaries of  novel 
science. However, with Peter’s research he emphasizes that it is important to choose targets 
carefully, as this will determine what scientific route will be taken.











“ Peter’s good at finding new techniques, and I help to get them 
to work. You certainly have to be prepared to try a lot of  new 
things, that seems to yield results”. 
 Sam Jamieson   SENIOR RESEARCH TECHNICIAN, DEPARTMENT OF BIOCHEMISTRY, 
 SCHOOL OF BIOMEDICAL SCIENCES
• Understanding the problem is important, with the ability to link basic science research 
through to ultimate impacts, even though these may be a long way off. Anita emphasises the 
need to understand the clinical problem when working in healthcare. This involves talking to 
clinicians to gain a good understanding of  current issues.
“ If  you’re going for impact in the health sector, you need to 
be thinking about the use of  your research. Make sure you 
understand the problem, and the clinical problem, and know 
what’s relevant”. 
 Dr Anita Dunbier   SENIOR LECTURER, DEPARTMENT OF BIOCHEMISTRY, 
 SCHOOL OF BIOMEDICAL SCIENCES
Grant applications
• Peter feels that the process of  writing grants, though sometimes laborious, is useful for 
developing ideas. It gets you thinking about possible impacts, and framing the research in 
its most impactful sense can be useful. Impact is an important component in engaging the 
assessment panel and saying why they should fund the research. 
Relationships
• Building personal relationships is a key component to achieving impact. Peter has identified 
people to work with, for example he approached Anita, in order to collaborate, after he 
initially found the link between Tribbles and breast cancer. This relationship has informed his 
knowledge of  the clinical relevance of  his own work.
• Similarly, other scientists have been interested in forming relationships with Peter because of  
the quality of  his research and because he filled a gap of  knowledge in the field.
Funding
• Obtaining consecutive grants (firstly from the Rutherford Discovery Fellowship for the 
preliminary work, then from the HRC) has enabled the research to develop, whilst also 
funding the capability-building of  staff in this research area. For example, the ongoing HRC 
funding received in 2015 allowed Sam to be employed as a research technician.
Dissemination
• Peter has observed that people are inherently interested in science, so it is important to  
talk to the public through the media. Peter finds this is generally received very positively –  
that it helps as a fundamental science researcher to realistically consider the ultimate  
potential for impact. 
• Conferences are important for networking and exploring new collaborations. This leads to a 
‘snowball effect’, where researchers are able to collaborate more.
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• Scientists have become more interested in the Tribbles work the more that it has been 
disseminated.
• Peter sees his job as providing useful information to people, so that other scientists who are 
studying these proteins are going to find the work useful.
What next?
• Further funding applications are now being considered to advance Tribbles work in 
leukaemia, generating reagents that can control protein levels in cells and assisting in 
structure-based drug design.  
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creating knowledge for change in medicines policy
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school of Pharmacy
(L-R): Professor Pauline Norris, Dr Simon Horsburgh
Summary of the impact
Professor Pauline Norris is a social pharmacy researcher who has achieved impact via advancing 
knowledge around social pharmacy, writing guidelines, and built academic capability in the 
students she works with. Pauline has achieved impact by answering research questions addressing 
current social issues, engaging meaningfully with stakeholders, collaborating with research partners, 
being adaptable, and disseminating findings in accessible ways.
“ Working with Pauline was awesome. I think she’s just 
amazing- she builds an impact and she’s so clearly focused on 
trying to improve things for people. It makes you feel like your 
research does have meaning.”
 Dr Simon Horsburgh   DEPARTMENT OF PREVENTIVE AND SOCIAL MEDICINE, 
 DUNEDIN SCHOOL OF MEDICINE
Underpinning research
Professor Pauline Norris is a social pharmacy researcher who aims to understand how people access 
and use medicines using social science methods. Social pharmacy is an applied research discipline 
which investigates the overlap between the social and behavioural sciences and pharmacy practice, 
including understanding and improving access to, use of, medicines. Pauline has undertaken 
research into a variety of  areas, including prescription charges, socioeconomic and ethnic variation 
in the use of  medicines, personal medicine storage, medicine availability and funding under 
PHARMAC (the Pharmaceutical Management Agency/Te Pātaka Whaioranga), and people’s 
knowledge and use of  antibiotics.
Prescription charges
Pauline undertook research into prescription charges in 2012 when the government increased the 
co-payment for prescription medicines to $5 (for up to 20 prescriptions, after which there should be 
no charge) from $3. Pauline’s research found that for the 10.3% of  New Zealanders living in poverty, 
paying $5 per prescription was prohibitive and meant people went without medication, putting their 
health at risk1. PHARMAC/Te Pātaka Whaioranga data highlighted by Pauline showed 40% of  New 
Zealanders continued to pay for 90% of  their prescription items, even after they reached 20 items, 
resulting in unnecessary spending of  $2.5 million1. Pauline’s research highlights that affordability of  
medicines is an easily-modifiable barrier to accessing healthcare. Qualitative research published in 
2016 showed people were forgoing prescription items, or making sacrifices such as delaying picking 
up medicines or reducing dosage due to cost, which comes with potential health risks2.
Socioeconomic and ethnic variation in use of medicines
Pauline became interested in socioeconomic variation in the use of  medicines once the means 
became available to study this - in the form of  the National Health Index (NHI) numbers used on 
all prescriptions since 2006. The Equity in Prescription Medicines Use study investigated issues around 
medicine access, including geographic access and access to different types of  drugs, using linked 
pharmacy data3-7. Part of  this study investigated antibiotic use in people of  different ethnicities 
in the Tairāwhiti (Gisborne) area4. It was undertaken in conjunction with Turanga Health (a 
Māori healthcare organisation) and Ngāti Porou Hauora (a Primary Health Organisation). The 
study found that antibiotic use was much lower amongst Māori, particularly in rural areas, than 
non-Māori. This was concerning as Māori have one of  the highest documented rates of  acute 
rheumatic fever and rheumatic heart disease in the world. 
People’s knowledge and use of antibiotics
Pauline’s research has further explored understanding of  antibiotic use in New Zealand, with 
ethnic variation in use and perceptions addressed amongst immigrant, Māori and Samoan 
populations. One study involved interviews with Samoans living in New Zealand about their 
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understanding and reported use of  antibiotics8. Results showed there was some confusion about 
antibiotic medicine. Less than 2% of  participants identified the correct purpose for antibiotics, and 
66% thought they were used to relieve pain. Respondents thought that a wide range of  medicines 
were classed as antibiotics. This has implications for health practitioners, as they should not assume 
Samoan patients share a Western scientific understanding of  antibiotics and illness8. 
Personal medicines storage
Pauline’s study on the storage of  medicines looked at how people store medicines and why9. Results 
revealed people often store medicines in places where temperature and humidity are likely to 
affect medicine quality and that items should not be stored in kitchens and bathrooms, in bags or 
cars longer than strictly necessary, or in a plane’s cargo hold. The authors recommended health 
professionals, particularly pharmacists, should emphasise the importance of  correct medicine 
storage, and that poor storage should be considered when medicines are not achieving their  
desired effect. 
Pharmac/Te Pātaka Whaioranga and medicines availability and funding in New Zealand
Pauline undertook research on perceptions of  medicine availability and funding through PHARMAC/
Te Pātaka Whaioranga10, who make decisions on which medicines are funded in New Zealand11. 
Respondents felt PHARMAC /Te Pātaka Whaioranga constrained medicine costs effectively, was 
politically neutral, and resistant to lobbying. Pauline also investigated the availability of  specific 
medicines in New Zealand, such as the breast cancer drug Herceptin12. Another study, undertaken 
with a PhD student, compared medicine availability and subsidisation in New Zealand and Finland13. 
Funding
• Health Research Council (HRC), (including $1 million project grant for  
the Equity in Prescription Medicines study and the current Prescription Charges  
study, a randomised controlled trial.
• Marsden Fund
• New Zealand Pharmacy Education and Research Fund
• Pauline has worked with multiple students, mainly of  Māori and Pasifika  
descent, who have obtained Summer Studentship funding from the HRC  
and the University of  Otago 
Research snapshot
• Pauline has produced 30 research articles on the topics included in this case study, which  
have been cited 321 times by authors in 61 countries14.
• Pauline’s research has been featured in a broad range of  New Zealand news media,  
including the Dominion Post, the New Zealand Herald, NewsHub, the Otago Daily Times, 
The Press, Radio New Zealand, stuff.co.nz, the Sunday Star Times, and the Star15-20. 
Details of the impact
Advancing knowledge
• Pauline aims to increase the awareness of  the public, pharmacists, and those concerned with 
medicine use, around social pharmacy issues such as prescription charges and medicines 
storage. An example of  this is the Twenty is Plenty campaign, a two-year initiative started in 
2016 by University of  Otago Pharmacy students. It was designed to inform the public that 
they only need to pay for a maximum of  twenty prescriptions per year, with any additional 
prescriptions being fully subsidised. The students put stickers on prescription bags, and created 
a Facebook page (receiving 461 likes and 454 follows)21, 22, Twitter account and YouTube 
channel. The students also attended community events, such as the Otago Farmers Market, to 
promote the campaign. 












• According to Andi Shirtcliffe (Chief  Advisor – Pharmacy at the Ministry of  Health), Pauline’s 
research on prescription charges has broadened the awareness of  issues with Ministry of  
Health Officials, and this, in turn, has had a positive impact on advancing policy discussions. 
It has also enabled the co-payment policy to be referred for consideration as part of  the 
Health and Disability System Review. 
• Pauline’s research underpinned a 2019 literature review by PHARMAC/Te Pātaka 
Whaioranga entitled Equitable access to medicines via primary healthcare23 and a discussion paper 
Achieving medicine access equity in Aotearoa New Zealand: towards a theory of  change24. 
• PHARMAC/Te Pātaka Whaioranga have presented the above work to stakeholders 
including the Ministry of  Health, District Health Boards and the Health Quality and Safety 
Commission, Primary Health Organisations, Pacific Health providers and Māori stakeholders 
(such as Whānau Ora collectives) at conferences and symposiums. Sandy Bhawan (Manager – 
Access Equity at PHARMAC/Te Pātaka Whaioranga) has noted that the discussion document 
on medicine access equity is of  potential use to stakeholders as it has been presented in a way 
that facilitates translation into policy.
“ For us, it’s so important to have those voices of  communities, 
and having their stories told through research.”
 Sandy Bhawan   MANAGER – ACCESS EQUITY,  
 PHARMAC/TE PĀTAKA WHAIORANGA
Guidelines
• Pauline was invited onto the group adapting the National Institute for Clinical Excellence 
(NICE) guidelines on antibiotic resistance for New Zealand, for the Best Practice Advocacy 
Centre (BPAC), published in 201725.
Capability building
• Student supervision has been a key factor in achieving impact. Pauline supported a PhD 
student, Shirley Keown from Turanga Health, through an HRC grant. This paved the way  
for an enduring relationship with the Māori healthcare organisation since 2006. Now Shirley 
is a co-investigator on the latest HRC grant, and Pauline is working with her on another  
HRC application. 
• Pauline has supervised many Pacific and Māori students through summer research 
studentships, enabling them to undertake projects that will benefit their own communities. 
• Pauline has also supported practising pharmacists to complete Masters degrees, enabling 
promotion into more senior positions.  





Answering the right questions
• Impact has been achieved by identifying and answering the questions that will be of  benefit to 
end users. This may be different from researching a topic that will get you a publication in a 
good journal or receive praise from colleagues.
“ I think that it would be better if  people were brave and tried to 
answer questions that the world needs an answer to.” 
 Professor Pauline Norris  CENTRE FOR PACIFIC HEALTH,  
 FORMERLY SCHOOL OF PHARMACY
Engagement and collaboration
• Face-to-face engagement has been a priority through all of  Pauline’s research. Making direct 
connections with people enables an understanding of  who is committed to pushing projects 
forward, as well as an understanding of  the local context. The annual visits by Pauline and 
Dr Simon Horsburgh, a co-researcher, to healthcare providers for The Equity in Prescription 
Medicines Use study  is one example of  Pauline’s engagement. Visits were facilitated by Dr 
Jenny Harre-Hindmarsh, Research Officer at Ngāti Porou Hauora. 
• Early engagement with key policy and implementation contacts in government is crucial. 
This can help test whether an idea will be able to achieve the desired impact. This was a key 
feature of  the work with Ngāti Porou Hauora and Turanga Health, where a local advisory 
group was set up to ensure research was going to benefit the community.
• Collaboration and co-creation of  projects has been essential for achieving impact. This 
involved harnessing the combined knowledge of  researchers and stakeholders, as well as the 
existing connections between pharmaceutical scientists and social pharmacists in the School 
of  Pharmacy. 
 “When you’re sitting here in Dunedin, you don’t really know 
the details of  how things work on the ground, whereas you go 
up there and you spend a couple of  hours chatting to people, 
and you realise why something has happened that way, or why 
something is not really accurate, because you’re missing out a 
whole lot of  something else that they do. You really need that 
local context.” 
 Professor Pauline Norris  CENTRE FOR PACIFIC HEALTH,  
 FORMERLY SCHOOL OF PHARMACY
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Responsiveness
• An awareness of, and a responsiveness to, emerging themes has been key to achieving impact. 
For example, findings of  the Prevalence and Extent of  Antibiotic Use study identified rheumatic 
fever as an important area for health policy and practice, and one that was also very relevant 
to the local community4. The findings were picked up by the media (for example,26, 27) and 
were widely publicised to illustrate inequities in antibiotic prescribing between Māori and 
non-Māori. These findings were used by politician Dame Tariana Turia in a speech to medical 
students, and in comment to the media saying that doctors are failing their patients28, 29.
Dissemination
• Pauline has actively disseminated her work beyond academic publications. This has included 
presenting at organisations such as PHARMAC/Te Pātaka Whaioranga, and writing press 
releases for a variety of  media formats, for example in newspapers29 and on the radio30.
• Dissemination of  research in multiple formats makes the key messages more accessible to the 
public as well as to government stakeholders and policy makers, encouraging them to take on 
board evidence-based messages. 
• It is important that communication is directly targeted at government stakeholders as, unless 
research is published in a seminal journal, it is unlikely to be seen and implemented. 
• Media exposure has increased interactions between the researchers and interested 
organisations.
What next?
• The ultimate aim of  Pauline’s research is to ensure people in New Zealand (and elsewhere) 
have access to medicines they need.
• Pauline is currently recruiting for a new study called Free Meds about prescription charges, 
aiming to ascertain the extent to which prescription charges are stopping patients from 
accessing medicines. This was featured on Radio New Zealand in January 202031.
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Summary of the impact
The world-leading research of  the Christchurch Heart Institute (CHI), based at the University of  
Otago, Christchurch, has influenced international clinical practice in the area of  heart failure (HF). 
The research team has undertaken pioneering work with B-type natriuretic peptide (BNP) and 
amino-terminal pro B-type natriuretic peptide (NT-proBNP), including the discovery of  circulating 
NT-proBNP. Both biomarkers are now widely used and endorsed by all authoritative international 
guidelines for HF diagnosis, prognosis and management. NT-proBNP is the single most widely 
used blood test (measured hundreds of  thousands of  times per year) for HF diagnostics and 
prognostics globally, resulting in improved health outcomes for patients and wider economic 
benefit. The impact of  the CHI is the result of  35 years of  sustained high-quality research from 
the team of  biomedical scientists and clinicians, through a desire to continuously improve patient 
outcomes and clinical practice.
“ The BNP story has had a major impact – it’s changed 
how people diagnose and treat heart failure, and to  
some extent heart attack, not only in New Zealand, 
but internationally. It has put New Zealand on the 
map, a contribution to the global effort.” 
 Professor Vicky Cameron  GROUP LEADER,  
 THE OMICS LABORATORY, CHRISTCHURCH HEART INSTITUTE
Underpinning research
The CHI was formerly named the Christchurch Cardioendocrine Research Group (CCERG) by 
Professor Richards when he recruited researchers from multiple disciplines to form a cohesive 
group in the 1990s. The CCERG represented a more formal alliance of  previous looser 
collaborations between Christchurch academic cardiology and endocrinology investigators, which 
had its origins in the early 1980s. Over the past 35 years the CHI has played a leading role in 
characterising the biochemistry, bioactivity and biomarker value of  a wide range of  peptides, 
most notably the natriuretic peptides (NPs) - circulating hormones generated by the heart – and 
developing these as cardiac biomarkers (indicators of  heart disease, such as HF). NPs participate in 
maintaining total body balance of  fluid and electrolytes and are therefore essential to life. 
HF occurs when the heart is unable to sustain an adequate circulation of  blood to meet the body’s 
needs1. It is a leading cause of  death and disability worldwide, affecting 80 000 New Zealanders2. 
HF has a high mortality rate, with up to 40% of  patients not surviving one-year post diagnosis3 
and 15-50% of  patients readmitted to hospital within 6 months of  discharge4. HF is the single 
most common cause of  medical admissions to hospital in those aged over 60 years. Internationally 
HF is responsible for ~2% of  total healthcare costs, with hospitalisation being a major cost to 
health care systems.5, 6 
The work of  the CHI team is comprehensive, with over 200 research papers produced on cardiac 
biomarkers in heart failure. Selected highlights are described in the following paragraphs.
Professor Mark Richards came to Christchurch in 1983. Just prior to this, in 1981, the first 
direct evidence of  the first NP to be discovered was published from a Canadian centre7. ANP 
(atrial natriuretic peptide, a type of  NP produced mainly by the atria8) was sequenced in 1984 by 
Japanese workers. Richards worked with pioneering colleagues Professor Gary Nicholls, Emeritus 
Professor Eric Espiner, Professor Hamid Ikram and Associate Professor Tim Yandle to provide the 
first data on the integrated cardiovascular, kidney and hormonal effects of  ANP in humans, and 
showing it was produced by heart tissue9. 
BNP (another type of  NP originating from the heart) was discovered in 1988 by Japanese scientists, 
and soon after this CHI researchers Professor Mark Richards, Emeritus Professor Eric Espiner 
and Associate Professor Tim Yandle developed an assay (a test to detect the protein). Associate 
Professor Tim Yandle and the cardiology team confirmed that BNP circulated in human plasma, 
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and that there was a different predominant form of  it in people with HF10. After studying different 
isoforms of  NPs and developing measuring methods, the idea was born to measure NT-proBNP 
(the inert fragment of  the pro-BNP hormone that is cleaved from the bioactive BNP peptide) levels 
as a biomarker of  HF. The group first published evidence of  circulating NT-proBNP in humans 
in 1995. Major commercial interest from Roche Pharmaceuticals in the CHI research sparked the 
creation of  the NT-proBNP test.
CHI researchers began using measurement of  BNP to test patients for acute heart failure in the 
Christchurch emergency department (ED) in 1993. Patients presenting with breathlessness were 
subjected to the test and Dr Mark Davis and the team showed that HF patients had high levels of  
BNP compared to those who did not have a cardiac problem. This was published in The Lancet in 
199411, triggering many replication studies around the world confirming that BNP is diagnostic of  
acute HF in people with shortness of  breath in the EDeg 12,13,14. 
The important results from the CHI research were later expanded in 2004, when Professor 
Mark Richards and Professor James Januzzi from the Harvard Medical School formed the 
International Collaborative of  NT-proBNP, or ICON research study15. This multi-centre, international 
study confirmed that NT-proBNP testing had high diagnostic value for detection of  acute heart 
failure and in predicting the prognosis of  patients with shortness of  breath who were suspected or 
confirmed to have acute HF. Furthermore, it provided important cut-off values of  NT-proBNP, 
now enshrined in international clinical guidelines, to guide clinical decision making.
The CHI conducted the first ever trial of  heart failure management guided by serial measurement of  
NT-proBNP20. This demonstrated benefit and triggered more than one dozen further trials by centres 
around the world. A meta-analysis of  worldwide studies involving over 2000 patients undertaken in 
201416, led by Professor Richard Troughton (Co-director Clinical Studies, CHI), provided compelling 
evidence that using BNP or NT-proBNP as a clinical guide (NP-guided patients) resulted in reduced 
all-cause mortality in those less than 75 years old. Additionally, hospitalisation due to heart failure or 
cardiovascular disease was significantly lower in NP-guided patients. 
A recent clinical trial17 has found that a new drug called Entresto, that acts in part by blocking the 
breakdown of  BNP and ANP, resulted in a 20% risk reduction in mortality and new hospitalisation 
for HF compared with those receiving current ACE-inhibitor therapy. This is the biggest 
improvement in HF therapies for 20 years.
The randomized clinical trial IMPERATIVE-HF, comparing peri-discharge management (adjusting 
treatment if  NP levels are raised) of  Acute Decompensated Heart Failure with usual clinical care, 
finished data collection in 202018. This trial will determine if  NP-guided care, around the time 
of  hospital admissions for episodes of  worsening heart failure, has better outcomes compared to 
standard care.
Key research of the CHI group includes:
• The first group to demonstrate the biological actions of  ANP in humans.
• Showing BNP can be used in the diagnosis of  HF (1994) and as an indicator of  disease status11. 
• Discovery of  NT-proBNP in 1995, which is part of  the BNP precursor19. 
• Being the first group to show that treatment for HF can be altered using NT-proBNP levels as 
a guide. This RCT was published in The Lancet (2000)20.
• Showing that NP levels increase after myocardial infarction (MI; heart attack), and can be 
used to predict outcomes in MI patients21.
• Further refining the use of  NPs in HF diagnosis, for example by studying NP levels in different 
age groups. 
• Improving the diagnostic performance of  NP tests. They have found that supplementing NT-
proBNP testing with mid-region pro-ANP or micro-RNA tests22 leads to improved diagnostic 
accuracy.
• Professor Richards has shown that BNP/NT-proBNP levels can identify patients who respond 
to heart failure treatments – in particular, he showed this for beta-blocker therapy in heart 
failure. It was shown that NT-proBNP and BNP above certain thresholds predict benefit from 
beta blocker therapy in coronary heart disease. 





• Health Research Council (HRC) - continuous Programme Grant funding for the past 27 
years, which has exceeded $20 million. Additionally, multiple HRC Project Grants have been 
funded, of  which four are current, including the IMPERATIVE-HF study.
• NZ Heart Foundation - multiple fellowships and project grants are held by group members.
• Since 1997 the Heart Foundation has funded Professor Mark Richards in its Chair of  
Cardiovascular Studies, which provides resources including long-term salary support for key 
CHI clinical and laboratory staff members. 
• Ministry of  Business, Innovation and Employment
• Canterbury Medical Research Fellowship (project grants and fellowships)
• Lotteries Health
• Christchurch Heart Institute Trust 
Research snapshot
• The team has produced over 200 papers on cardiac biomarkers in heart failure.
• The article Treatment of  heart failure guided by plasma amino-terminal brain natriuretic peptide (N-BNP) 
concentrations from 200017 has over 1200 citations23.
• CHI research on NT-proBNP has been cited in 117 granted patents in the United States and 
Australia (PatCite).
• There has been extensive news coverage on the research within New Zealand (for example, 
the New Zealand Herald24, the Otago Daily Times25 and the Press26, as well as overseas in 
Australia27, China28 and South Africa29.
Details of the impact
Heart Failure treatment guidelines
Research from the CHI has appeared in multiple international guidelines, including:
• The American Heart Association (AHA) Guideline for the Management of  Heart Failure30 
have made Class I (strong) recommendations for the use of  biomarkers in diagnosis and 
prognosis. The AHA has also released a Scientific Statement on the Role of  Biomarkers for 
the Prevention, Assessment, and Management of  Heart Failure, citing CHI work31.
• UK National Institute for Health and Care Excellence (NICE) Guidelines on Acute Heart 
Failure32.
• The European Society of  Cardiology Acute and Chronic Heart  
Failure Guidelines33.
• The National Heart Foundation of  Australia and Cardiac Society  
of  Australia and New Zealand: Guidelines for the Prevention,  
Detection, and Management of  Heart Failure in Australia34.
Clinical application
• NT-proBNP is the single most widely used blood test (measured hundreds  
of  thousands of  times per year) for HF diagnostics and prognostics globally. 
• NT-proBNP is used as an inclusion criterion and as a surrogate endpoint  
for HF trials. It helps to select the right participants for trials and to  
indicate presence or lack of  benefit from innovative therapies. 
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• Use of  NT-proBNP has been shown to be cost effective in multiple international studies3, 35-37. 
One study showed the use of  NT-proBNP decreases the lifetime cost of  care per patient by 
$176 000 USD for men, and $101 000 USD for women35. Another showed NT-pro BNP use 
reduces the medical costs of  ED visits, hospitalisations and outpatient services37.
Health outcomes
• Patients are diagnosed with HF faster and more accurately, leading to shorter hospital stay30, 33, 
reduced stay in ED31, fewer readmissions to hospital31 and reduction of  the mortality rate 3, 32. 
• Patients experience better quality of  care, improved quality of  life, and improved wellbeing 3, 
35, 36.
• There is a reduction in hospitalisations and intensive care admissions38.
Commercialisation
• Major commercial interest was received from Roche Diagnostics, who led the development of  
NT-proBNP as a test. 
• Professor Mark Richards is a founder, and Associate Professor Chris Pemberton is a founder 
and Chief  Scientific Officer of  the spin-out company Upstream Medical Technologies. This 
company is developing tests to speed up the diagnosis of  another heart condition, unstable 
angina25.
Further research
• Thousands of  papers have now been written on BNP and NT-proBNP from a worldwide 
network of  people, which is incrementally adding to CHI research. The Medline database 
shows 13,799 articles have been written on BNP since 199039.
Teaching
• The CHI team is engaged in postgraduate supervision and the teaching of  advanced degrees 
across preclinical basic science and in clinical areas in order to develop the next generation of  
researchers, who will further improve clinical outcomes for patients.
Pathway to impact
Collaboration
• The research environment and infrastructure has been important to enhance the collaborative 
nature of  CHI studies, in particular the recent NT-proBNP studies, which have been 
nested within clinical care and integrated with the Canterbury District Health Board and 
Christchurch Hospital.  
• The CHI has a strong working relationship with Professor Rob Doughty’s group at the 
University of  Auckland (and prior to that Professor Norman Sharpe). For example,  
IMPERATIVE-HF is a two-centered study conducted in partnership with Auckland.
• There has been an excellent link between endocrine and cardiology researchers, basic 
scientists and clinicians within the CHI, resulting in ongoing fruitful cross-disciplinary 
conversation and mutual support.
• In 2016-7, the CHI launched a charity partnership with Ryman Healthcare and received 
$330,000 of  funding to undertake a study about cardiovascular disease risk in New Zealand’s 
retirement healthcare sector40. Residents take part in research trials and benefit from 
education and improved care through this process.
• Other researchers actively seek to collaborate with CHI. Currently, 29% of  CHI research 
output on BNP has been done with collaborating authors (SciVal).




• The CHI has strong international collaborative links. Being located in New Zealand, away 
from large centers of  cardiovascular research presents challenges. In recent years Professor 
Richards has spent a proportion of  his time at the National University of  Singapore, as 
founder of  that University’s Cardiovascular Research Institute (CVRI), enabling access to 
large cohorts of  Asian patients and expanding collaboration for the CHI. The CHI is also 
been a part of  major international research studies, for example the ICON, GREAT, MAGGIC, 
GIANT and BIOS  biomarker and heart failure research consortia15.
“ What sets them apart from a lot of  very successful 
research teams is their collaborative nature, which has 
increased the impact of  the research that  
they’ve done.” 
 Professor James Januzzi   HARVARD MEDICAL SCHOOL &   
 CARDIOLOGIST,  MASSACHUSETTS GENERAL HOSPITAL, US.
Community engagement
• Community engagement is a large part of  the CHI ethos. The senior leaders of  the group 
have given over 90 public lectures in the past five years, including to the University of   
the Third Age, Probus, Rotary, and talks in conjunction with the Heart Foundation and 
Ryman Healthcare. 
• Hui are arranged with Māori participants, and studies are designed to oversample Māori and 
Pacific participants.
“ We must give talks to the general public. Don’t be shy about saying 
“‘this is what I do, and this is how your money is being used.”’ 
 Research Associate Professor Chris Pemberton 
 DIRECTOR,TRANSLATIONAL BIODISCOVERY LABORATORY,  
 CHRISTCHURCH HEART INSTITUTE
Planning for impact
• Undertaking basic work on the biology of  NPs and then in parallel subsequently developing 
their application as clinically useful biomarkers is an excellent example of  translational (bench 
to bedside and back) research.
Publicity
• CHI researchers actively take opportunities to publicise their work. For example, Professor 
Mark Richards has spoken to members of  learned societies on over 280 occasions.
• By disseminating research results, traction is gained for further research and for application 
of  the research. For example, with BNP, American and European interest was generated in 
the early 2000s, resulting in translation to treatment guidelines and the NT-proBNP test being 
created by Roche Diagnostics.
• The CHI uses the media team at the University of  Otago to distribute press releases. This 
helps to inform the public and other scientists about the research they are doingeg 41. The CHI 
leadership also independently interacts with print and visual media and coordinates its own 
newsletter and Facebook account.  
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What next?
• Research Associate Professor Chris Pemberton and Dr Andree Pearson are leading a study 
called CHAMPIONZ looking at cardiovascular risk in residents in the Ryman rest homes.
• The current HRC Programme Grant is wrapping up, so planning is underway for the area 
of  focus for the next Programme Grant, which will be on acute coronary heart disease and 
its management. Coronary heart disease is the major precursor to heat failure. This work will 
take advantage of  the improved integration of  health data sets and information, including 
the All New Zealand Acute Coronary Syndrome Quality Improvement (ANZACS-QI) registry. The other 
theme of  this work will be tailoring treatment to fit individual patients.
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Summary of the impact
The research of  Dr Don Schwass, a dentist, Senior Lecturer and researcher at the University 
of  Otago, focusses on the incorporation of  silver nanoparticles into dental materials to confer 
antimicrobial properties, and the development of  novel dental materials for restorative dentistry. 
These products are to combat the bacterial dental infections of  caries (tooth decay), periodontitis 
(gum disease) and peri-implantitis (infections around dental implants). In partnership with Dr 
Carla Meledandri from the Department of  Chemistry and Dr Gemma Cotton from the Faculty of  
Dentistry, this research resulted in the filing of  three patent families, one of  which was licensed to a 
multinational dental manufacturing company. A spinout company (Silventum) has been formed in 
order to commercialise the research. Through the research process, Dr Gemma Cotton has gained 
her PhD and became an employee of  Silventum, whilst continuing her research career. This has 
resulted in improved capability of  the research team.
Underpinning research
Periodontitis is a bacterial infection of  the bone and supporting tissues surrounding the teeth1. It is 
associated with an inflammatory response to dental plaque at the gum margin, and can ultimately 
cause a loss of  teeth. Increasingly, tooth loss is treated using titanium dental implant screws to 
which crowns are attached. These implants are expensive and vulnerable to further gum disease 
such as peri-implant mucositis – an inflammatory reaction in the gum tissue around the implant, 
or peri-implantitis which affects the supporting bone, causing the loosening of  the implant and 
its eventual failure2. Current treatment strategies for periodontitis and peri-implantitis involve 
mechanical debridement and antibiotics, which have limited success as they slow the progression 
of  disease, but do not cure it2. Treatment with antibiotics also carries the risk of  inducing bacterial 
antibiotic resistance, making it harder to treat the infection2.
Don’s research interest is in devising novel treatments for dental caries that are less invasive and 
less destructive of  the tooth than traditional methods. Dental caries can occur when bacteria 
generating acid demineralises tooth enamel and causes cavities. Don’s first interest was to develop 
a product that would disinfect dentine, the tooth layer beneath enamel, that had been infected 
by bacteria from caries. Current treatment of  caries is to ‘fill’ the cavity with a restoration, but 
often the decay is not completely eliminated. If  the seal around the restoration breaks down the 
remaining bacteria can cause further caries. Don’s objective was to develop a substance that would 
completely inactivate any bacteria remaining in the dentine. Ideally, the substance would remain in 
the dentine and protect it from further bacterial invasion. 
In 2010 Don went to a three-day induction course as a new academic staff member at the 
University of  Otago. This course included a ‘speed-collaborating’ exercise, where staff members 
paired off and had to introduce themselves and discuss their research interests. In this exercise 
he met Dr Carla Meledandri, a chemist with expertise in nanoparticle research. They realised 
that Carla’s expertise combined with Don’s interest in solving clinical problems had significant 
collaboration potential. Don explained to Carla what he wanted from his novel material – an 
antimicrobial silver formulation that would not stain dental enamel. Carla saw how she could 
manipulate the silver nanoparticle size to prevent it from staining. They applied for an Otago 
Innovation Limited Proof-of-Concept grant, and won, which provided the initial funding for  
this research.
The first product patented was an antimicrobial solution of  colloidal silver nanoparticles that look 
like water. The product did not discolour teeth, which was important for aesthetic reasons. Silver 
nanoparticles naturally aggregate, so ligands were used to create micellar structures that held 
the silver nanoparticles apart. There was a lot of  in vitro testing and antimicrobial studies, with 
approximately 200 iterations before the first product was formulated. Don and Carla developed the 
product further so that it could be forced into tooth dentinal tubules by iontophoresis – by applying 
a charge to the tooth. A similar approach had been successfully used in the past when applying 
fluoride to teeth. Through this advance they produced an antimicrobial compound that binds to 
the tooth and could be forced deep into exposed dentine.
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Following the development of  the colloidal product they collaborated with Professor Warwick 
Duncan (Head of  the Discipline of  Periodontology, at the University of  Otago) to make an 
antimicrobial for use in periodontal treatments. They generated a gel that could be used in 
the mouth around teeth and gums that would degrade at a rate that is optimal for tissue repair 
following dental procedures or dental surgery. Professor Duncan used his established model of  
periodontitis in sheep, and developed a novel model for peri-implantitis in sheep to test the gel.
The third product made by the researchers was a silver nanoparticle-containing glass ionomer 
cement with antimicrobial properties for use as a dental filling restorative material.  
Funding
• Proof  of  Concept grant, Otago Innovation Limited
• Partners for Innovation grant
• Otago Innovation research contracts and commercialisation resources (including patent filing, 
legal, regulatory consultants, and marketing)
• Otago Innovation Limited’s devolved MBIE PreSeed Accelerator Fund
• Powerhouse investment leveraging matching Callaghan Innovation repayable loans (MBIE 
startup funding)
• University of  Otago Research Grants
• MacDiarmid Institute
Research snapshot
• Dr Don Schwass and Dr Carla Meledandri have four publications from this work3-6.
• Three patented technologies have patents filed7-9, two have been filed nationally in multiple 
jurisdictions (including Europe, the US, Australia and New Zealand). There is one granted 
US patent for the first technology.
• The work has been featured in the media, including the Otago Daily Times10, and in an 
interview with The Science Show on ABC Radio National (Australia)11.
Recognition
• Dr Carla Meledandri won the 2017 Prime Minister’s MacDiarmid emerging scientist award, 
based partly on this work.
• Dr Gemma Cotton is a graduate of  the Kiwinet Emerging Innovator Programme  
and a commercialisation consultant for Momentum (Return on Science).  
Details of the impact
Spin-out company
• In 2014, the spin-out company Silventum was formed, which will commercialise novel  
nano-chemistry technology developed from this research. It is currently owned by  
Otago Innovation (58.82% shares) and Powerhouse Ventures (41.18% shares).  
• The creation of  Silventum led to the exclusive licensing of  the third (restorative material) 
technology, and a non-exclusive license for the second (gel) technology.
• Don, Carla and Gemma are founding staff members of  Silventum. At its peak,  
it employed four people (2.0 FTE).











• Dr Gemma Cotton conducted her PhD with the research team exploring the development 
of  silver nanoparticle-based oral materials. Gemma continued working in the team for a year 
as a Research Fellow, and as Chief  Technology Officer at Silventum. She is now a Research 
Fellow working with Professor Warwick Duncan and Associate Professor Dawn Coates.
Potential impact
• The ultimate goal of  this research was to take the patented restorative product to market.  
This has been pursued with great effort (see ‘commericalisation’ under ‘pathway to impact’). 
It is hoped current research on a fourth product – looking at a new dental filling material that 
is closer to a tooth’s composition – will support this goal. 
• Silventum hopes to gain further investment via Powerhouse Ventures and additional  
external investors.
• One of  the goals of  Silventum is to manufacture their products in Dunedin, which will bring 
benefit to the local economy, resulting in job creation.
• There is potential to develop the products in the area of  animal health. 
• Whichever product(s) reach the market will change healthcare practice, resulting in greater 
prevention of  bacterial dental infections. Health benefits include improved wellbeing for 
patients. There will also be economic impact in reducing the cost of  treatment.
Pathway to impact
Addressing real-world problems
• Dr Don Schwass, with 20 year’s clinical experience, is a passionate believer in addressing real-
world problems with research. By reverse engineering clinical problems, he has been able to 
keep a strong applied focus to his product development.
• Dr Gemma Cotton wanted to conduct research in this area due to her parents’ dental issues; 
she was able to visualise the impact of  the research might have on them.
“ I really wanted to solve problems for society. The reason 
why I joined their team originally was that my parents 
had dental issues and so I took their problems and put 
it into what we were trying to address.” 
 Dr Gemma Cotton  POSTDOCTORAL FELLOW,  
 SIR JOHN WALSH RESEARCH INSTITUTE, FACULTY OF DENTISTRY
High quality research
• Publishing high quality research papers has been a good marketing tool for the patented 
technology. Additionally, the University of  Otago has a great reputation, so industry partners 
feel they can rely on the quality of  the research.
Commercialisation
• The pathway to patenting, licensing and regulatory approval is complex, and Don and Carla 
have worked closely with Otago Innovation Limited through this process. Dr Alex Tickle 
(Commercialisation Manager at Otago Innovation Limited) became involved once the 
product was patentable and became project manager. They worked on the provisional patent, 
developing the business plan and finding industry partners and external investors. Don and 
Carla were involved in developing a regulatory approval pathway for the first product (the 
colloid) together with a contracted regulatory consultant and later with the licencee. 
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• There is a balance between patenting and publication, as information about the technology 
cannot be in the public arena prior to patenting, and therefore publication plans are often 
delayed. This means that researchers may need alternative ways to maintain the publishing 
requirements for their academic job – for Don this meant participating in other research 
projects whilst the patenting process was taking place.
• Don’s experience as a clinical dentist were crucial in the initial stages of  scoping the products. 
• Don’s contacts as a clinical dentist supported the development of  a network for market 
validation with dental companies.
• Carla and Don travelled to the United States, Germany and Liechtenstein to have meetings 
with major dental manufacturing companies interested in investing in their technology. Otago 
Innovation organised confidentiality agreements in advance. The fact that these companies 
were prepared to enter into these confidential discussions commends the relevance and 
novelty of  this research and the existing relationships Don had with some of  these companies. 
• KiwiNet (an organisation supported by the Ministry of  Business, Innovation and 
Employment, of  which Otago Innovation Limited is a member) gave advice and support, and 
provided additional industry contacts.
• Dr Gavin Clark, former CEO of  Silventum and former Director of  Research & Enterprise 
at the University of  Otago, recommends that researchers approach Otago Innovation 
Limited early in the research process if  they believe that they have an invention that may have 
commercial value. 
Gaining regulatory approval
• Gaining regulatory approval allowing the technology to be used in patients can be challenging. 
The original product (the colloid) was exclusively licensed to a dental material company, but as 
it was too novel compared to existing products and classified as a therapeutic product it had a 
complex regulatory route, which proved a challenge to navigate. 
• The second product (the gel) was also classified as a therapeutic product and faced similar 
challenges to the first product.
• Following their experience with the two therapeutic products, Don and Carla realised there 
might be better opportunities in designing dental materials, which for regulatory purposes are 
classified as medical devices, and have a quicker and easier regulatory approvals route to market. 
• Once the third product (the restorative material) was created, this led to the formation of  
the spin-out company Silventum. Silventum obtained the exclusive rights to the restorative 
material, as well as a non-exclusive license to the gel to avoid any freedom to operate. 
They worked through regulatory pathways to see if  they could get a product including the 
restorative material technology onto the market, which has not yet been able to occur. Don 
and Carla were frequently consulted through this process to verify the technical information.
Collaboration
• The success of  this research has been built on the cross-disciplinary collaboration between 
Don and Carla, and also by bringing in additional experts such as Professor Warwick Duncan.
“ I guess I’ve just been a bit fortunate, because of  the way I’ve thought 
about clinical problems and also landed on very good collaborations, 
that has just meant that all the stars have lined up nicely.” 
 Dr Don Schwass  SENIOR LECTURER, DEAN’S OFFICE (DENTISTRY),  
 FACULTY OF DENTISTRY





• Don presented research ideas at the European Organisation for Caries Research, where it was 
perceived as being highly novel and relevant.
• Otago Innovation Limited provided a demonstration video, patent information and the 
research team’s publications to a wide range of  dental companies. The University of  Otago’s 
press release about the exclusive licence of  the colloid reached dental journals as far as the 
East Coast of  the United States. This resulted in dentists approaching Otago Innovation to 
access Don’s invention. 
What next?
• Current research at Silventum is on a fourth product, aiming for a new dental filling material 
that is closer to a tooth’s composition. 
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Summary of the impact
Disability should not be a barrier for access to parks, which are important for physical health 
and social wellbeing. The Parks for Activity and Recreation in the Community (PARCs) study led by Dr 
Meredith Perry, a Senior Lecturer, researcher and physiotherapist in the School of  Physiotherapy 
at the University of  Otago Wellington, looks at access to parks for persons with a disability. Social 
ecological barriers can limit persons with disabilities’ journey to, entry into, and full use of  a park 
and its facilities. Through the PARCs research, Meredith created a tool which is used to evaluate 
park infrastructure against national and international minimum standards or legislative rights 
for disability access. Meredith’s research aims to change policy around park design, in order to 
promote equity in access and usability of  parks for persons with a disability. She has worked with 
multiple community organisations and city councils to achieve impact. The PARCs tool has been 
widely used to evaluate park access, and findings used in advocacy and lobbying to support council 
policy change. 
Underpinning research
Parks, which are a component of  greenspace, help to improve physical activity levels, and thus the 
health and wellbeing of  the population1. Increasingly, parks are being recognised as supporting 
social cohesion and building community resilience2, 3. Dr Meredith Perry became interested in 
equity of  access to parks for persons with a disability (including long-term health conditions) in 
2016. In New Zealand, 25% of  people self-report a disability, with this rising to over 64% in adults 
>65 years old4. Access to parks may be limited by the routes to and within the park, including 
parking and pathways, and also by the facilities and amenities, such as play areas, rest areas, toilets 
and drinking fountains. Equity in park access is important, particularly as community members 
with a long-term condition or disability are more at risk of  developing health comorbidities related 
to physical inactivity5. A systematic review undertaken by Meredith and colleagues on park-based 
physical activity interventions for persons with disabilities identified health outcomes from health 
outcomes from park-based interventions 5p19 (Figure 1).
FIGURE 1:  HEALTH OUTCOMES OF PARK-BASED INTERVENTIONS 
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Meredith developed an evaluation tool called the PARCs tool to determine whether a park meets 
disability access requirements. The 50-item tool comprises of  questions divided into sections 
covering many aspects of  accessibility6 Appendix A: supplementary data. This tool has been used in an 
evaluation of  21 parks in three metropolitan areas of  New Zealand6. No parks met the national 
standards and/or international guidelines for park and playground design, and the study identified 
areas for improvement. Figure 2 outlines the results of  the audit.
 FIGURE 2 -  RESULTS OF AUDIT OF 21 PARKS IN THE WELLINGTON AREA
This tool is now being used by multiple councils around New Zealand to evaluate their parks. 
Meredith has been working with organisations (such as Public Health South, Rotary and Inner 
Wheel, CCS Disability Action and the Blind Foundation), and councils across New Zealand to 
implement the use of  the tool. City councils are able to use the PARCs tool to assess park access 
against international human rights laws and the United Nations Convention on the Rights of  
Persons with Disabilities (which New Zealand has signed).
In a further study (unpublished), Meredith conducted a survey of  1000 older adults and found 
private vehicle use to (OR 3.99 (1.48, 10.8)), and mobility within (OR 9.55 (1.95, 46.8)) the park 
significantly influenced park use in older adults with disability. Significantly more older adults with 
a disability had not visited an urban park in the last month than older adults without a disability. 
Older adults with disability enjoy visiting parks because this allows them to risk-take, feel socially 
connected, and it was perceived to improve health and wellbeing. However, qualitative interviews 
found the effort of  negotiating inaccessible areas, the reliance on family members to support them 
moving freely through the park and no or limited accessible amenities (i.e. toilets) was off-putting.
Meredith has also interviewed 17 children and their whānau about their experiences of  park 
use (unpublished). This research revealed only one child could visit their  local neighbourhood 
park. The 16 others had to travel considerable distances to be able to participate in any  park 
related activities. Whānau and the children appreciated going to the park as  they challenged 
the children’s capabilities and independence, offered a multi-sensory environment that benefited 
physical, psychological and social wellbeing and provided a place for the family to be together. The 
inaccessibility of  their local parks made children with disability and their whānau feel excluded. 
“ This research is about creating the places and spaces that 
give the best benefit to the population that it serves.” 
 Dr Meredith Perry  SCHOOL OF PHYSIOTHERAPY,  
 THE UNIVERSITY OF OTAGO, WELLINGTON





• University of  Otago Research grant 
• Porirua City Council
• Collaboration of  Ageing Research Excellence Summer Student Grant 
Research snapshot
• There are two research publications from this work5, 6.
• Meredith’s research is highlighted on the Activity & Nutrition Aotearoa7,  
Office for Disability Issues8, Plimmerton Rotary9 and Porirua City10 websites.
Details of the impact
PARCs tool used in evaluation
• Since Meredith’s initial study, the PARCs tool has been  
used nationally and internationally to evaluate park access.  
The Playable Porirua audit was undertaken on all 41 parks 
 in the Porirua Area, supported by Plimmerton Rotary and  
Porirua Rotary, and the Inner Wheel Club of  Plimmerton,  
with the research team led by Meredith providing training  
and support9. The findings were used to make submissions to  
Porirua City Council regarding changes that could be made.
“ Having that audit tool to be able to say ‘this is the state  
of  the playground that you’re talking about’, and  
‘this is what’s required to bring it up to scratch’,  
and ‘these are the costs that are involved in doing  
that’, is very, very valuable” 
 Adrienne Murray   ASSISTANT GOVERNOR FOR DISTRICT 9940  
 OF ROTARY, MEMBER OF PLIMMERTON ROTARY CLUB AND     
 PLIMMERTON INNER WHEEL
• Dr Pauline Boland, Lecturer at the University of  Limerick (Ireland) teaches in a graduate 
entry programme for Occupational Therapy students. She uses part of  the PARCs tool in her 
lecture on inclusive design. Students then use the tool to audit their campus to gain awareness 
of  what may be challenging for those with a disability. She also illustrates how the PARCs tool 
can be used for lobbying authorities, and supporting clients to make statements about public 
spaces not accessible to them. Pauline had two Occupational Therapy Masters students in 
2017 who, between them, audited about 50 parks in Limerick and Kerry. The findings of  this 
study have been submitted to two county councils who gave consent for the audits to occur for 
their consideration in updating current parks and designing future ones. 
• University of  Otago Master of  Dietetics students on placements with Public Health South 
(PHS; the public health unit at the Southern District Health Board) have developed a 
questionnaire focusing on the water fountain section of  the PARCs tool. Drinking fountains 
were chosen to support PHS work in promoting water as the drink of  choice. The students 
evaluated seven fountains in Dunedin and four in Invercargill and presented their results to 
PHS and CCS Disability Action staff. A report was also prepared which was subsequently 
used to advocate for improved drinking fountains with the Invercargill City Council’s Parks 
and Reserves departments. 









• Community groups are able to use the PARCs tool to evaluate parks, and the results can 
then be used for advocacy purposes. Raewyn Hailes, Access and Community Development 
Manager at CCS Disability Action, has completed park audits for multiple councils in the 
Wellington area. The Rotary Club are trying to get training in the use of  the PARCs tool so 
they can incorporate it into their District Plan in Plimmerton, and also into the national plan, 
led by Adrienne Murray (Assistant Governor District 9940 of  Rotary).
• Waitaki District Council have been using the PARCs tool in an accessibility study in Oamaru. 
The West Coast Regional Council have begun an audit using the PARCs tool.
• Discussions are underway with the Dunedin City Council to evaluate their parks. Training  
on the PARCs tool for Dunedin Council Staff was completed in March 2019.
Environmental change
• Submissions and discussions from the use of  the PARCs tool by the Master of  Dietetics 
students helped to inform the choice of  a drinking fountain for the Bluff Community.
• Dunedin City Council have installed a wheelchair-accessible fountain in Caversham Reserve 
using the PARCs tool in August 2019. The council are now investigating putting similar 
fountains in the proposed George St upgrade.
Policy change
• A draft policy change at Porirua City Council called Playable Porirua is a 10-year planning 
document informed by the Playable Porirua audit8. This provides guidance for playgrounds 
and will come up for review in 2022. The council will then go through the formal policy 
process, including community consultation, and they will take the document specific to 
playgrounds and integrate it into the Reserves Management Plan. At the moment Playable 
Porirua is classified as a ‘working policy’ – it is being implemented without yet being 
formalised.
• PHS staff have developed a guidelines document for choosing drinking fountains, and this is 
recommended by CCS Disability Action. 
Pathway to impact
Collaboration
• A key feature of  Meredith’s research has been her close relationship with community 
organisations such as Rotary, Inner Wheel and CCS Disability Action, as well as local councils. 
• Members of  community organisations and councils value collaborating with Meredith and 
her colleagues at the University of  Otago, saying their reputation meant the research was 
taken seriously. This is important in a challenging funding environment where councils 
operate on three-year cycles and have multiple potential projects to fund.
 “ Having the reputation of  Otago University and the 
Physiotherapy School in behind what we’re doing,  
having that name attached to the Playable Porirua 
work has just been valuable to getting councillors  
on board, getting the community on board and  
telling people that we are serious about accessible 
playgrounds and parks.” 
 Olivia Dovey   PARKS MANAGER, PORIRUA CITY COUNCIL





• Meredith spoke at multiple national and international conferences to disseminate this work, 
enhancing the uptake of  the research by organisations and councils. She presented her 
research at:
– The New Zealand Recreation Association conference in 2017 to parks and green space 
policy directors11.
– The International Society for Physical Activity and Health (ISPAH) in London in 2018, 
the biggest international physical activity conference in the world12. 
– The Active Living and Environment International Symposium at the University of  Otago 
in 201713.
– The Physiotherapy New Zealand conference in 201814.
• Meredith, Olivia Dovey (Parks Manager, Porirua City Council), Christine Jacobson (Senior 
Policy Analyst Porirua City) and Adrienne Murray (Assistant Governor for District 9940 of  
Rotary) were invited to attend the IMPACT Conference hosted by the University of  Otago 
in 201715 where they led a workshop about the project. Considerable interest was expressed 
by the audience comprising social research staff, health policy advisors and council members 
from around the country.
What next?
• Meredith would like to publish the PARCs tool in a free format that councils or other 
organisations can use.
• Meredith has two project ideas for the future; to formally evaluate a park before and after the 
PARCs tool intervention, and to create a park in conjunction with council from the bottom 
up – an inclusive park design. This would be best achieved via co-creation with the disability 
community.
• Meredith’s ultimate goal is to make every park in New Zealand fully accessible. 
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What can we learn from these case studies?
Four key themes were identified in these case studies that guided the pathway to achieving research 
impact; meaningful engagement, broad dissemination, an inclusive culture, and high quality 
research. These themes have allowed us to identify some steps researchers can undertake to 
increase the impact of  their work.
1. Meaningful engagement
Study participants emphasised the need for meaningful engagement with a variety of  groups, 
including the community to which the research is related, the media, policy makers, clinicians and 
next-users of  the research. Researchers indicated the importance of  identifying collaborators and 
end-users early, in order to shape the research question, get ongoing feedback, and open up further 
networking opportunities. Stakeholders spoke of  feeling like true partners in the research process, 
and that research results could be easily translated into practice. Researchers actively planned 
engagement activities, as well as taking advantage of  opportunities as they arose.
“ A meaningful relationship is not just about completing a 
research study and that’s the end. It can also involve a 
relationship outside of  research in supporting your community 
partner to come and speak in their own rights about the 
research experiences that they’ve had, rather than maybe the 
university taking on that lead and going to all the conferences.” 
Cheryl Davies  
MANAGER OF TŪ KOTAHI MĀORI ASTHMA TRUST,  
REGARDING HE KAINGA ORANGA
2. Broad dissemination
Means of  communicating research results included public forums, panel discussions, blogs, press 
releases, parliamentary submissions, hui and providing comment to the media. Dissemination 
enabled engagement as it generated debate and discussion about the research. Dissemination 
was a key tool in advancing knowledge about the research topic to a wider audience, and allowed 
increased visibility of  the research, therefore increasing the chance of  impact.
“ One of  the things that I teach all my students and younger, 
emerging, staff is that I’m really big on communicating 
research to the lay community. They want to know the impact. 
They want to know what it’s doing for them.” 
 Professor Mark Richards  DIRECTOR, CHRISTCHURCH HEART INSTITUTE
Research impact for researchers
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3. An inclusive culture
An inclusive culture supports impact. Impact is person-led, with principal investigators and 
research teams often being instrumental in creating cultures of  collaboration and forward-thinking. 
It was identified that involving students in research led to a positive research environment as 
students are excited about research and learning, and researchers enjoyed teaching and up-skilling 
students. Teams that were inter-disciplinary were able to achieve impact in multiple areas, as 
research results were meaningful to a wider group of  end-users. Finally, principal investigators 
were often described as exhibiting strong leadership skills by being able to bring together groups of  
people to work on a project, and being strongly focussed on achieving impactful results.
“ Peter just for some reason plants a seed in these students,  
and it grows out that they are willing to work really hard on 
the project and get enthusiastic about it, and they do really 
well. That also sparks the interest in the students to progress 
into science.”  
 Assistant Professor Raymond Staals  
 THE UNIVERSITY OF WAGINENGEN, THE NETHERLANDS,  
 REGARDING PETER FINERAN
4. High quality research
Research impact is built on high-quality science and research. Participants acknowledged that 
publishing research in leading journals meant this could be used as a stepping stone or lever 
to achieve impact.  Research targeted at addressing topics of  need, or ‘hot topics’ was seen as 
important by stakeholders. 
“ Having published in the BMJ and The Lancet, the World 
Health Organisation came to me quite early on and said,  
‘We really like your work. Would you like to come, first of  all, 
to look at housing and health?.’ And then I was asked to chair 
this guidelines group.”  
 Professor Philippa Howden-Chapman  HE KAINGA ORANGA
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Research impact is an important concept to understand when planning and implementing 
research. Impact can be planned, but is inherently non-linear and unpredictable, so it is important 
to constantly assess the environment and respond accordingly.
1. Make a plan
Identify the types of  impacts you are wanting to achieve. A framework such as that of  Cruz Rivera 
et. al1 can help to identify types of  impacts to aim for. If  applying for a grant, look at the guidelines 
to assess what types of  impacts are important to the funder. Guidance on impact is available 
from the Health Research Council2 and Ministry of  Business, Innovation & Employment3. 
Logic models (for example, Figure 1) provide a helpful tool for planning impact – inputs include 
resources required for the research and who will be involved; activities occur during the research to 
support impact (see point 2); outputs are what is produced as a results of  the research, for example 
publications and reports; outcomes are what occurs after research is taken up by stakeholders or end-
users, for example changing the way people work or influencing decision-making; and impacts are 
the difference that research has made, and can include health, social, economic and environmental 
benefits, as well as benefits to equity.
 
FIGURE 1:  AN EXAMPLE OF A LOGIC MODEL
A tailored knowledge translation and/or dissemination plan can facilitate the transfer of  research 
knowledge to the end-user(s).
2. Engage in activities to support impact
Activities that may help to enhance the impact of  research include identifying and collaborating 
with stakeholders, and co-producing or co-designing research. Relationships are the cornerstone to 
achieving impact. With Māori stakeholders or participants, it may be important to arrange specific 
engagement activities such as hui. Communication skills are key to relationship-building.
Understanding the wider environment in which you are working is crucial for impact. For example, 
you may need to time your research to fit in with local government funding cycles, or there may be 
policy windows during which you need to engage with policy makers.
Knowledge translation may involve arranging meetings to disseminate research. It may be 
necessary to disseminate research in different formats to different audiences, for example in press 
releases, lay summaries or clinical protocols.
undertaking impactful research
INPUTS activitieS outputS outcomeS impactS
1. Cruz Rivera S, Kyte DG, Aiyegbusi OL, Keeley TJ, Calvert MJ. Assessing the impact of healthcare research: A systematic review of methodological frameworks. 
PLoS Medicine. 2017;14(8):e1002370.
2. HRC NZ. 2020 Research Impact Assessment2020. Available from: https://www.hrc.govt.nz/sites/default/files/2019-09/2020%20Research%20Impact%20
Slideshow%20with%20notes.pdf.
3. Ministry of Business Innovation & Employment. The Impact of Research. 2019.
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3. Measure your impact
Measurement of  impact is important when articulating the impact of  research to research funders, 
and also establishing your impact track record when applying for further funding. Any evidence 
of  impact – for example evidence of  your research being incorporated into guidelines, research 
referenced in policy, engagement with communities or a commercial partner – should be recorded.
University of  Otago library staff support the gathering of  traditional and alternative impact 
metrics. With access to a number of  key research analytics tools, and expert knowledge in 
bibliometrics and emerging trends in research impact, librarians can support both individual 
researchers and groups to identify top performing publications, demonstrate international reach 
and collaboration, and locate evidence of  impact beyond academia. Examples include citations per 
publication, publications in top journal percentiles, references to publications in public policy, and 
news media mentions.   
Subject Librarians are available to work with individual researchers to provide evidence of  impact 
and develop strategies for increasing impact. Research Services Librarians are available to create 
metrics reports at research unit, departmental level, or above. Both subject and research services 
librarians collaborate to ensure the best outcome. 
Consult the Library Liaison Service guide https://otago.libguides.com/liaison to contact your 
Subject Librarian. 
Consult the Research Support Unit guide https://otago.libguides.com/RSU for more 
information on Research Services Librarians. 
To learn more about measuring publication impact consult the Research Publishing & Impact 
guide: https://otago.libguides.com/research_publishing_impact
IMPACTS OF RESEARCH  |   PA G E  6 7
impacts 
of research
PA G E  6 8   |   IMPACTS OF RESEARCH
impacts 
of research
division of health sciences
t e  w Ā h a n g a  M Ā t a u  h a u o r a
impacts 
of research
Division of Health Sciences
Te Wāhanga Mātau Hauora
